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CHAPTER I 
 
A NEW METHODOLGY TO ACCESS MEDIUM-RING AZABICYCLIC RING 
SYSTEMS: SYNTHESIS OF INDOLIZIDINE, PYRROLO[1,2-A]AZEPINE, 
PYRROLO[1,2-A] AZOCINE AZABICYCLES AND SYNTHESIS OF 
RELEVANT AZABICYCLIC LACTAMS 
 
1.1. Introduction 
 The azabicyclic ring system is a common structural subunit present in numerous 
alkaloid natural products and serves as an important scaffold in biologically active and 
pharmaceutically significant compounds. Pyrrolizidine, indolizidine, pyrrolo[1,2-
a]azepine, and pyrrolo[1,2-a]azocine are common examples of the azabicyclic ring 
system (Figure 1.1). Due to the importance of this ring system, we felt it warranted our 
attention to develop a rapid a versatile approach to access this ring system. Additionally, 
azabicyclic lactams are also a prevalent motif in a variety of natural products and 
biologically relevant compounds. A slight modification to the approach of generating 
azabicyclic ring systems that could be applied to synthesizing azabicyclic lactams would 
be desired. 1,2,3,4 
N
pyrrolo[1,2-a]azepine
N N
pyrrolo[1,2-a]azocineindolizidine
N
pyrrolizidine
N N N
OOO  
Figure 1.1  Azabicyclic ring systems and azabicyclic lactams 
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1.2.  Background to Synthetic Approach 
Magnesium or indium mediated enantioselective additions into sulfinyl aldimines, 
work pioneered by Ellman and coworkers in 2009 was the initial inspiration for our route 
to azabicyclic ring systems. As seen in Scheme 1.1, Ellman’s work involves the addition 
of Grignard additions of an alkyl bromide bearing a latent aldehyde moiety into chiral N-
sulfinyl aldimines. This enantioselective addition is dictated by the chirality of the t-
butylsulfinamide allowing for the generation of new alkyl group stereocenters. A 95:5 
trifluoroacetic acid:water mixture allows for deprotection of latent aldehyde and the N-
sulfinyl substituent which undergoes an intramolecular reductive amination to form the 
imine, whereupon the addition of triethylsilane as a hydride source, gives the chiral 2-
substituted pyrrolidine.5 
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Scheme 1.1 Ellman’s approach to chiral 2-substituted pyrrolidines 
 
 Our group envisioned taking Ellman’s work further and accessing diverse 
azabicyclic ring systems. Starting with more functionalized N-sulfinyl aldimines, through 
a number of functional group transformations and manipulations, we could 
enantioselectively generate, depending chirality of the tert-butylsulfinyl, indolizidine, 
pyrrolo[1,2-a]azepine, and pyrrolo[1,2-a]azocine azabicyclic ring systems and the 
relevant azabicyclic lactams (Scheme 1.2).6 
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Scheme 1.2 Enantioenriched azabicyclic rings via chiral sulfinamides.  
 
1.3. Synthesis of Indolizidine Ring System 
The protocol we envision to generate a diverse array of azabicyclic ring systems 
involves a protocol of an asymmetric Grignard or indium mediated allylation, N-
alkylation, ring closing metathesis (RCM), and finally an intramolecular reductive 
amination, or cyclization, to generate the desired enantiopure azabicycle.  
The strategy began with commercially available aldehyde 1.1 which was 
condensed with chiral tert-butylsulfinamine 1.2 and copper sulfate to generate (R)-N-
sulfinylaldimine 1.3 in 91% yield (Scheme 1.3). Next, a stereoselective indium-mediated 
addition of allyl bromide in a saturated aqueous sodium bromide solution into N-
sulfinylaldimine 1.3 generates a new chiral stereocenter in the allylated 1.4 product in 
87% yield. The diastereomeric ratio (d.r.) for this reaction was greater than 19:1 of the 
desired stereoisomer, which could separated through normal phase flash column 
chromatography, and the d.r. verified through either HPLC or proton NMR comparison. 
This secondary amine was then alkylated using allyl bromide and lithium 
hexamethyldisilazide (LHMDS) as the base to generate the dialkene product 1.5 in 80% 
yield. This was then refluxed with Grubbs 2nd generation catalyst in CH2Cl2 to undergo a 
ring closing metathesis reaction to form the unsaturated piperadine derivative 1.6 in 84% 
yield. The alkene was then subjected to a palladium catalyzed reductive hydrogenation to 
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generate the saturated six-member ring. Next, the crude material from the previous 
reaction is subjected to a global deprotection of the sulfinyl and the acetal to expose the 
amine and aldehyde. This spontaneously undergoes a reductive amination the form the 
imine, whereupon treatment with polymer supported triacetoxyborohydride in 
dichloroethane generates the enantiopure indolizidine product 1.7 in 81% yield from 
intermediate 1.6, which happens to be the natural product (+)-coniceine.  
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Scheme 1.3 Synthetic route generate the indolizidine azabicycle 
 
The (+) or (-) enantiomer of the indolizidine azabicycle can be rapidly generated 
depending on the chirality of the sulfinamide starting material used. Indolizidine 1.7 
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could be accessed in 6 steps with an overall yield of 43% starting from commercially 
available materials. 
 
 
1.4. Synthesis of Pyrrolo[1,2-a]azepine 
Next, we sought to synthesize the pyrrolo[1,2-a]azepine using similar key 
reactions of an asymmetric addition into a chiral N-sulfinyl aldimine, a ring closing 
metathesis reaction catalyzed by a Grubbs 2nd generation catalyst, and finally a global 
deprotection/reductive amination to generate the ‘5,7’ azabicyclic ring system. 
The synthetic route for this azabicyclic adduct begins with a condensation 
between aldehyde 1.8 and the chiral tert-butylsulfinamide 1.2 with Ti(OEt)4 to remove 
water from the reaction which generates N-sulfinylaldimine 1.9 (Scheme 1.4). An 
enatioselective addition a Grignard reagent 1.10 into N-sulfinylaldimine 1.9, where the 
addition is directed by the existing chirality of the starting material substrate, forms the 
N-sulfinylamine 1.11 in excellent yield and a d.r. of more than 9:1. Next, alkylation with 
allyl bromide, and LHMDS as the base, gives the bis-alkene product 1.12 in 80% yield 
where the diastereomers can be separated from the previous Grignard addition by normal 
phase column chromatography.  
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Scheme 1.4 Synthetic route to the azabicycle pyrrolo[1,2-a]azepine 
 
With dialkene 1.12 in hand, we then subjected it to a ring closing metathesis 
reaction to form the unsaturated 7-membered ring 1.13 in 78% yield by refluxing in 
dichloromethane for 1 hour. Next, a reductive hydrogenation with palladium on carbon 
and hydrogen gas at room temperature in methanol gives the fully saturated 7 membered 
ring. From here it was one more step of a global deprotection of the sulfinyl and acetal 
with a 95:5 trifluoroacetic acid:water mixture to expose the amine and aldehyde, 
respectively. This intermediate than undergoes an intramolecular reductive amination 
whereupon treatment with polymer-supported triacetoxyborohydride gives the desired 
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pyrrolo[1,2-a]azepine 1.14 in 81% yield over two step, from the Grubbs cross metathesis 
reaction. Overall, the pyrrolo[1,2-a]azepine ring systems was generated from 
commercially available starting materials in 6 steps and 45% overall yield.  
 
 
1.5. Synthesis of Pyrrolo[1,2-a]azocine 
The next ring system we sought to synthesize was the pyrrolo[1,2-a]azocine 
azabicyclic compound. Again, the robust and versatile methodology used to generate the 
indolizidine and pyrrolo[1,2-a]azepine is used make the pyrrolo[1,2-a]azocine desired 
scaffold. The route again uses key reactions of an asymmetric addition into a chiral N-
sulfinyl aldimine, a ring closing metathesis reaction catalyzed by a Grubbs 2nd generation 
catalyst, and finally a global deprotection/reductive amination to generate the ‘5,8’ 
azabicyclic ring system. 
This strategy begins with commercially available aldehyde 1.15 which was 
condensed with chiral tert-butylsulfinamine 1.2 and copper sulfate to generate (R)-N-
sulfinylaldimine 1.16 in 91% yield (Scheme 1.5). Next, a stereoselective indium-
mediated addition of allyl bromide in a saturated aqueous sodium bromide solution into 
N-sulfinylaldimine 1.16 generates a new chiral stereocenter in the allylated 1.17 product 
in 87% yield. The diastereomeric ratio (d.r.) for this reaction was greater than 19:1 of the 
desired stereoisomer, which could separated through normal phase flash column 
chromatography, and the d.r. verified through either HPLC or proton NMR comparison. 
From here alkylation with 5-bromo-1-pentene, and again LHMDS as a base, generates 
the bis-alkene product 1.18 in 85% yield. 
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 Scheme 1.5 Synthetic route to the azabicycle pyrrolo[1,2-a]azocine 
 
 Next, a ring closing metathesis reaction of bis-alkene 1.18 with Grubbs 2nd 
generation catalyst generates the unsaturated 8-membered ring 1.19 by refluxing in 
dichloromethane in 82% yield. The unsaturated 8-membered ring is saturated using 
palladium on carbon and hydrogen in ethanol to undergo a reductive hydrogenation to 
give the fully saturated 8-membered ring system. From here it was one more step of a 
global deprotection of the sulfinyl and acetal with a 95:5 trifluoroacetic acid:water 
mixture to expose the amine and aldehyde, respectively. This intermediate than 
undergoes an intramolecular reductive amination to give the imine intermediate 
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whereupon treatment with polymer-supported triacetoxyborohydride gives the desired 
pyrrolo[1,2-a]azocine 1.20 in 87% yield over two steps, from the Grubbs cross 
metathesis reaction. Overall, the pyrrolo[1,2-a]azocine ring systems was generated from 
commercially available starting materials in 6 steps and 43% overall yield. 
 
  
1.6. Synthesis of Azabicyclic Lactams 
Using a slight variation of the approach to generate the indolizidine, pyrrolo[1,2-
a]azocine, and pyrrolo[1,2-a]azocine azabicyclic ring systems, we can rapidly and 
efficiently form diverse azabicyclic lactams. This is another motif commonly found in a 
range of natural products and also pharmaceutically relevant compounds. The approach 
used to synthesize these compounds is also highly convergent where a deviation in one of 
the final steps allows for easy access to a variety of azabicyclic lactams. 
The synthetic route (Scheme 1.6) begins with a condensation between aldehyde 
1.21 and tert-butylsulfinamide 1.25 in dichloromethane with copper sulfate to remove 
water from the system to generate the chiral N-sulfinylaldimine 1.22 in 91% yield. From 
here, we use a similar enatioselective indium-mediated addition of allyl bromide in 
saturated aqueous sodium bromide to generate a new stereocenter in the olefin product 
1.23 in 88% yield and greater than 9:1 d.r.. The two diastereomers can be easily separated 
by normal phase column chromatography to give the desired compound. Next, 
deprotection of the N-sulfinyl aldimine with 6N HCl in 1,4-dioxane exposed the primary 
amine that, after concentration in vacuo, is then treated with sodium carbonate to undergo 
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a lactamization between the amine and the methyl ester to give chiral γ-lactam 1.24 in 
excellent yield of 97% over the two steps. 
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Scheme 1.6 Synthetic route to the chiral γ-lactam 
 
 From this point in the synthetic scheme, the next step is alkylation of the 
secondary amide. Depending upon the alkylating reagent, the desired azabicyclic lactam 
can be accessed rather efficiently and in a rapid manner. The “5,6” azabicyclic lactam can 
be formed treatment with LHMDS followed by allyl bromide to alkylate to the tertiary 
amide. This can then be subjected to a ring closing metathesis reaction using Grubbs 2nd 
generation catalyst to give the unsaturated 6 membered ring in 87% yield over 2 steps.  
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Scheme 1.7 Formation of enatiopure γ-azabicyclic lactam 
 
The “5,7” azabicyclic lactam can be formed in a similar manner by treatment with 
LHMDS followed by butenyl bromide to alkylate to the tertiary amide. This can then be 
subjected to a ring closing metathesis reaction using Grubbs 2nd generation catalyst to 
give the unsaturated 7 membered ring in 86% yield over 2 steps. The “5,8” azabicyclic 
lactam can be formed again the same manner by treatment with LHMDS followed by 5-
bromo-1-butene to alkylate to the tertiary amide. This can then be subjected to a ring 
closing metathesis reaction using Grubbs 2nd generation catalyst to give the unsaturated 
8- membered ring in 73% yield over 2 steps. The alkene in all of the azabicyclic lactams 
can then be used as a functional handle to further diverse and functionalize to access a 
wide array of compounds.7 
With this methodology of accessing azabicyclic clearly demonstrated to be 
successful, we next sought to apply this to the indolizidine containing natural product 
grandisine D and the pyrrolizidine containing natural product cremastrine.  
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1.7 Experimental Section 
Flame-dried (under vacuum) glassware was used for all reactions. All reagents and 
solvents were commercial grade and purified prior to use when necessary. All polymer-
supported reagents were purchased from Biotage, Inc. Thin layer chromatography (TLC) 
was performed on glass-backed silica gel. Visualization was accomplished with UV light, 
and/or the use of anisaldehyde and ceric ammonium molybdate solutions followed by 
charring on a hot-plate. Chromatography on silica gel was performed using Silica Gel 60 
(230-400 mesh) from Sorbent Technologies. IR spectra were recorded as thin films and 
are reported in wavenumbers (cm-1). 1H & 13C NMR spectra were recorded on Bruker 
DRX-400 (400 MHz) or Bruker AV-NMR (600 MHz) instrument. Chemical shifts are 
reported in ppm relative to residual solvent peaks as an internal standard set to δ 7.26, δ 
77.0 (CDCl3) and DMSO-d6 2.50 ppm, 39.51 ppm for 1H, 13C respectively). Data are 
reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, dd = doublet of doublets, br = broad, m = multiplet), coupling constant (Hz), 
integration. Optical rotations were measured on a JASCO P-2000 digital polarimeter. 
Concentration (c) in g/100 ml and solvent are given in parentheses. Low resolution mass 
spectra (LCMS) were obtained on an Agilent 1200 LCMS with electrospray ionization. A 
Micromass Q-Tof API-US mass spectrometer was used to acquire high-resolution mass 
spectrometry (HRMS) data.  The value Δ is the error in the measurement (in ppm) given 
by the equation Δ = [(ME – MT)/ MT] × 106, where ME is the experimental mass and MT is 
the theoretical mass.  The HRMS results were obtained with ES as the ion source and 
leucine enkephalin as the reference.   
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(R)-2-methyl-N-(pent-4-en-1-ylidene)propane-2-sulfinamide (1.9).  
4-pentenal (11.89 mmol, 0.5 g) was dissolved in THF (40 mL) and Ti(OEt)4 (23.79 
mmol, 2 eq.) was added followed by (R)-(+)-2-methyl-2-propanesulfinamide (2.0 mmol, 
1.0 eq.). The mixture was stirred at rt for 5 h. The reaction is then quenched by addition 
of an equal volume of sat. NaHCO3. The resulting mixture is filtered through a pad of 
Celite® and the filter cake rinsed washed with EtOAc. The filtrate was extracted with 
EtOAc (3 x 40 mL), the combined organic layer was washed with water, brine and dried 
over magnesium sulfate. Concentration in vacuo gave the crude aldimine which was 
purified by flash chromatography (4:1 to 1:1 Hex/EtOAc) to yield the desired product 
2.11 g (95%) as a colorless oil: [α]D
20 = +276.3 (c = 1.00, CHCl3); 1H NMR (400.1 MHz, 
CDCl3) δ (ppm): 8.08 (t, J = 4.4 Hz, 1H), 5.83 (m, 1H), 5.05 (m, 2H), 2.62 (m, 2H), 2.40 
(q, J = 6.8, 2H);  13C NMR (100.6 MHz, CDCl3) δ (ppm): 168.7, 136.6, 115.7, 56.4, 35.2, 
29.2, 22.2; HRMS (TOF, ES+) C9H18NOS [M+H]+ calc'd 188.1131, found 188.1130. 
 
NH
O
OS
O
 
(R)-N-((S)-1-(1,3-dioxan-2-yl)hept-6-en-3-yl)-2-methylpropane-2-sulfinamide (1.11). 
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Magnesium turnings (4.99 g, 205.2 mmol) were flame dried with catalytic amount of 
Iodine in 500 mL reaction flask.  70 mL of THF was added, followed by dropwise 
addition of 2-(2-Bromoethyl)-1,3-dioxane (6.94 mL, 51.3 mmol). The reaction mixture 
was periodically cooled in a rt water bath to prevent refluxing. After addition of the 2-(2-
bromoethyl)-1,3-dioxane solution was complete, the reaction mixture was stirred for 1 h. 
The solution was then transferred to a different flask and was cooled to −78 ◦C. Upon 
cooling, precipitate was observed and to the solid N-tert-Butanesulfinyl imine (1.63 g, 
10.26 mmol) in 20 mL THF was added dropwise to the Grignard solution, the solution 
was stirred for overnight at −48 ◦C and then warmed to rt. The reaction mixture was 
quenched with sat NH4Cl and extracted with EtOAc (3 x 40 mL).  The organic layer was 
dried over sodium sulfate.  Concentration in vacuo gave crude product as >9:1 dr, which 
was then purified by  flash chromatography (4:1 to 1:1 Hex/EtOAc) to yield the product 
2.74 g (88%) as a pale yellow oil: [α]D20 = +55.1 (c = 1.00, CHCl3); 1H NMR (400.1 
MHz, CDCl3) δ (ppm): 5.80 (m, 1H), 5.05 (dd, J = 8.7, 17.2 Hz, 1H), 4.97 (dd, J = 8.4 
Hz, 1H), 4.51 (t, J = 4.4 Hz, 1H), 4.07 (dd, J = 10.8, 5.2 Hz, 2H), 3.75 (dt, J = 12.4, 2.0 
Hz, 2H), 3.23 (m, 1H), 3.05 (d, J = 6.8 Hz, 1H), 2.15 (q, J = 7.6, 2H), 2.07 (m, 1H), 1.56-
1.75 (m, 6H), 1.54 (m, 1H), 1.33 (d, J = 13.6 Hz, 1H), 1.20 (s, 9H);  13C NMR (100.6 
MHz, CDCl3) δ (ppm): 137.9, 115.1, 101.9, 101.8, 66.8, 58.7, 56.2, 55.7, 36.9, 35.4, 31.2, 
29.8, 29.7, 25.7, 25.6, 22.6; HRMS (TOF, ES+) C15H30NO3S [M+H]+ calc'd 304.1946, 
found 304.1945. 
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N
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(R)-N-((S)-1-(1,3-dioxan-2-yl)hept-6-en-3-yl)-N-allyl-2-methylpropane-2-sulfinamide 
(1.12).   
To a solution of (303 mg, 1 mmol) in DMF (2.8 mL) at -20 oC was added 1 M LiHMDS 
in THF (1.76 mL, 1.76 mmol) dropwise. The mixture was stirred for 20 mins and allyl 
bromide (0.43 mL, 5 mmol) was added. After stirring for 2 h, the reaction was quenched 
with sat. NH4Cl, extracted with EtOAc (3 x 10 mL).  The organic layer was washed with 
water, brine and dried over Na2SO4.  Concentration in vacuo gave the residue which was 
then purified by automated flash chromatography (4:1 Hex/EtOAc) to yield the product 
274.4 mg (80%) as a pale yellow oil: [α]D20 = -40.5 (c = 1.00, CHCl3); 1H NMR (400.1 
MHz, CDCl3) δ (ppm): 5.71-5.89 (m, 2H), 5.15 (m, 2H), 4.98 (m, 2H), 4.49 (t, J = 5.2 
Hz, 1H), 4.08 (dd, J = 11.6, 4.4 Hz, 2H), 3.95 (dd, J = 16.4, 5.2 Hz, 1H), 3.73 (t, J = 12.4 
Hz, 2H), 3.11 (dd, J = 16.4, 7.2 Hz, 2H), 2.93 (m, 1H), 2.17 (m, 1H), 2.05 (m, 2H), 1.87 
(m, 1H),  1.70 (m, 1H), 1.62 (m, 4H), 1.32 (d, J = 13.6 Hz, 1H), 1.19 (s, 9H);  13C NMR 
(100.6 MHz, CDCl3) δ (ppm): 137.9, 136.1, 117.4, 114.8, 101.9, 66.8, 57.8, 45.1, 33.0, 
32.8, 30.7, 27.6, 25.7, 23.6; HRMS (TOF, ES+) C18H34NO3S [M+H]+ calc'd 344.2259, 
found 344.2260. 
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(S)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((R)-tert-butylsulfinyl)-2,3,4,7-tetrahydro-1H-
azepine (1.13).  
To a solution of (195.7 mg, 0.57 mmol) in CH2Cl2 (60 mL) was added 2nd Gen. Grubbs 
(24.2 mg, 0.028 mmol). The mixture was refluxed for 1 h and concentrated. The resulting 
crude product was purified by automated flash chromatography (4:1 to 1:1 Hex/EtOAc) 
to yield the desired product 140.2 mg (78%) as yellow oil: [α]D20 = +27.5 (c = 0.55, 
CHCl3);  
1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.71 (m, 1H), 5.62 (m, 1H), 4.54 (t, J = 4.8 Hz, 
1H), 4.11 (dd, J = 7.4, 4.8 Hz, 2H), 3.64-3.88 (m, 4H), 3.52 (m, 1H), 2.28 (m, 2H), 2.05 
(m, 2H), 1.86 (m, 1H), 1.58-1.73 (m, 4H), 1.33 (q, J = 13.6 Hz, 1H), 1.2 (s, 9H);  13C 
NMR (100.6 MHz, CDCl3) δ (ppm): 131.1, 128.8, 102.1, 66.8, 60.8, 58.4, 42.3, 32.3, 
32.2, 27.6, 25.7, 25.0, 23.5; HRMS (TOF, ES+) C16H30NO3S [M+H]+ calc'd 316.1946, 
found 316.1946. 
O
O
N
S
O
 
(R)-N-(3-(1,3-dioxan-2-yl)propylidene)-2-methylpropane-2-sulfinamide (1.3).  
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To a solution of 3-(1,3-dioxan-2-yl)propanal (2.1 g, 14.6 mmol) in CH2Cl2 (100 mL) was 
added (R)-2-methylpropane-2-sulfinamide (2.12 g, 17.5 mmol) and CuSO4 (7.0 g, 43.8 
mmol). The reaction mixture was stirred at rt overnight. The mixture was filtered through 
a through celite pad and washed with CH2Cl2. Concentration in vacuo gave the crude 
product which was purified by automated flash chromatography (4:1 to 1:1 Hex/EtOAc) 
to yield the desired product 1.91 g (91%) as yellow oil: [α]D20 = -208.8 (c = 0.86, CHCl3); 
1H NMR (400.1 MHz, CDCl3)  
δ (ppm): 8.11 (t, J = 4.0 Hz, 1H), 4.62 (t, J = 4.8 Hz, 1H), 4.10 (dd, J = 6.0, 4.8 Hz, 2H), 
3.76 (m, 2H), 2.64 (sextet, J = 4.0 Hz, 2H), 2.07 (m, 1H), 1.93 (m, 2H), 1.32 (dm, J = 
13.8 Hz, 1H), 1.18 (s, 9H);  13C NMR (100.6 MHz, CDCl3) δ (ppm): 169.1, 101.0, 67.0, 
56.7, 30.8, 30.7, 25.8, 22.5; HRMS (TOF, ES+) C11H22NO3S [M+H]+ calc'd 248.1320, 
found 248.1319. 
O
O
HN
S
O
 
(R)-N-((R)-1-(1,3-dioxan-2-yl)hex-5-en-3-yl)-2-methylpropane-2-sulfinamide (1.4).   
In-Mediated allylation were done according to procedures published by Lin and co-
workers. To a reaction flask containing (1.1 g, 4.45 mmol) and indium powder (2.05 g, 
17.8 mmol) was added saturated aqueous NaBr solution (90 mL) followed by the allyl 
bromide (1.54 mL, 17.8 mmol). The resulting suspension stirred at rt overnight. The 
reaction was quenched by the addition of saturated aqueous NaHCO3 and filtered through 
a pad of celite. The aqueous layer was extracted with EtOAc (3x), dried over Na2SO4, 
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filtered, concentrated in vacuo to give the crude product as >19:1 dr, which was then 
purified by  flash chromatography (1:1 Hex/EtOAc) to yield the allylation product 1.12 g 
(87%) as a pale yellow oil: [α]D20 = -46.4 (c = 1.79, CHCl3); 1H NMR (400.1 MHz, 
CDCl3) δ (ppm): 5.77 (m, 1H), 5.16 (d, J = 4 Hz, 1H), 5.13 (s, 1H), 4.51 (t, J = 4.5 Hz, 
1H), 4.08 (dd, J = 5.0, 6.3 Hz, 2H), 3.74 (dt, J = 10, 2.2 Hz, 2H), 3.30 (m, 1H), 3.23 (d, J 
= 6.5 Hz, 1H), 2.37 (m, 2H), 2.05 (m, 1H), 1.63 (m, 3H), 1.33 (br, J = 14 Hz, 1H), 1.19 
(s, 9H);  13C NMR (100.6 MHz, CDCl3) δ (ppm): 133.9, 119.0, 101.9, 66.8, 55.8, 55.0, 
40.5, 31.3, 29.2, 25.7, 22.6; HRMS (TOF, ES+) C14H28NO3S [M+H]+ calc'd 290.1790, 
found 290.1790. 
 
General Procedure for N-alkylation: 
To a solution of sulfinamide (1 equiv), in DMF at -20 oC was added LiHMDS (1 M, 1.0 
equiv) and the mixture was stirred for 20 mins. Bromide (1.5 equiv.) was then added 
slowly to the mixture and the reaction was stirred for 3 hrs at rt.  The reaction was 
quenched with saturated NH4Cl solution and extracted with EtOAc (3x).  The combined 
organic extracts were washed with water and the dried over Na2SO4. Filtration and 
concentration afforded the crude product, which was purified by flash chromatography 
(4:1 Hex/EtOAc).  
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N S O
O
O  
(R)-N-((R)-1-(1,3-dioxan-2-yl)hex-5-en-3-yl)-N-allyl-2-methylpropane-2-sulfinamide 
(1.5). The product was prepared according to the general procedure using allyl bromide. 
The reaction was run on a 1 mmol scale, to afford the product as a off white gum (263.2 
mg, 80%): [α]D
20 = +40.1 (c = 1.11, CHCl3); 1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.82 
(m, 2H), 5.03-5.21 (m, 4H), 4.49 (t, J = 4.8 Hz, 1H), 4.07 (dd, J = 6.8, 4.8  Hz, 2H), 3.94 
(dd, J = 11.6, 5.2 Hz, 1H), 3.74 (t, J = 12.0 Hz, 2H), 3.20 (dd, J = 9.6, 6.8 Hz, 1H), 3.09 
(q, J = 6.8 Hz, 1H), 2.24-2.41 (m, 2H), 2.34 (t, J = 6.2 Hz, 1H), 1.83 (m, 1H), 1.65-1.73 
(m, 2H), 1.62 (m, 1H), 1.33 (d, J = 13.6 Hz, 1H), 1.19 (s, 9H);  13C NMR (100.6 MHz, 
CDCl3) δ (ppm): 136.5, 135.9, 117.4, 117.1, 102.2, 67.0, 58.2, 45.2, 39.1, 33.0, 27.6, 
25.9, 23.9; HRMS (TOF, ES+) C17H32NO3S [M+H]+ calc'd 330.2103, found 330.2104. 
N S O
O
O  
(R)-N-((R)-1-(1,3-dioxan-2-yl)hex-5-en-3-yl)-2-methyl-N-(pent-4-en-1-yl)propane-2-
sulfinamide (1.12).  
The product was prepared according to the general procedure using 5-bromopent-1-ene. 
The reaction was run on a 1 mmol scale, to afford the product as yellow oil (303.4 mg, 85 
α]D
20 = +39.7 (c = 0.91, CHCl3); 1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.79 (m, 2H), 
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5.03 (m, 4H), 4.51 (t, J = 4.8 Hz, 1H), 4.07 (dd, J = 6.8, 4.8  Hz, 2H), 3.94 (dt, J = 12.0, 
2.4 Hz, 2H), 3.23 (m, 1H), 3.06 (q, J = 6.4 Hz, 1H), 2.56 (m, 1H), 2.33 (m, 2H), 2.07 (m, 
3H), 1.59-1.86 (m, 6H), 1.32 (d, J = 13.6 Hz, 1H), 1.19 (s, 9H);  13C NMR (100.6 MHz, 
CDCl3) δ (ppm): 137.8, 136.0, 117.1, 115.14, 102.3, 67.0, 66.9, 57.9, 42.8, 39.2, 33.1, 
31.6, 29.6, 28.0, 24.0; HRMS (TOF, ES+) C19H36NO3S [M+H]+ calc'd 358.2416, found 
358.2416. 
 
N
O
O
S
O
 
(R)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((R)-tert-butylsulfinyl)-1,2,3,6-tetrahydropyridine 
(1.6).  
To a solution of (200 mg, 0.61 mmol) in CH2Cl2 (65 mL) was added 2nd Gen. Grubbs 
(25.9 mg, 0.030 mmol). The mixture was refluxed for 1 h and concentrated. The resulting 
crude product was purified by automated flash chromatography (4:1 to 1:1 Hex/EtOAc) 
to yield the desired product 154.2 mg (84%) as off white solid: [α]D20 = +20.7 (c = 1.05, 
CHCl3);  1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.69 (m, 2H), 4.53 (t, J = 5.2 Hz, 1H), 
4.10 (dd, J = 7.6, 4.0 Hz, 2H), 3.85 (m, 1H), 3.76 (tt, J = 12.0, 2.8 Hz, 2H), 3.29-3.40 (m, 
2H), 2.55 (m, 1H), 2.01-2.13 (m, 1H), 1.85-1.91 (m, 2H), 1.70-1.79 (m, 1H), 1.57-1.66 
(m, 2H), 1.34 (d, J = 13.6 Hz, 1H), 1.16 (s, 9H);  13C NMR (100.6 MHz, CDCl3) δ (ppm): 
125.26, 123.57, 102.17, 67.00, 58.62, 56.90, 36.46, 32.86, 28.16, 26.88, 25.85, 23.49; 
HRMS (TOF, ES+) C15H28NO3S [M+H]+ calc'd 302.1790, found 302.1788. 
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(R)-8-(2-(1,3-dioxan-2-yl)ethyl)-1-((R)-tert-butylsulfinyl)-1,2,3,4,7,8-
hexahydroazocine (1.19). To a solution of 1.18 (217.8 mg, 0.61 mmol) in CH2Cl2 (65 
mL) was added 2nd Gen. Grubbs (25.9 mg, 0.030 mmol). The mixture was refluxed for 1 
h and concentrated. The resulting crude product was purified by automated flash 
chromatography (4:1 to 1:1 Hex/EtOAc) to yield the desired product 178.6 mg (82%) as 
off white solid: [α]D20 = +24.6 (c = 1.16, CHCl3);  1H NMR (400.1 MHz, CDCl3) δ 
(ppm): 5.75 (m, 2H), 4.52 (t, J = 4.4 Hz, 1H), 4.09 (m, 2H), 3.75 (m, 3H), 3.19 (m, 2H), 
2.3-2.4 (m, 2H), 2.15-2.2 (m, 1H), 1.98-2.1 (m, 2H), 1.53-1.8 (m, 5H), 1.45 (m, 1H), 1.30 
(d, J = 13.6 Hz, 1H), 1.18 (s, 9H);  13C NMR (100.6 MHz, CDCl3) δ (ppm): 132.3, 127.6, 
102.5, 67.0, 66.9, 58.2, 45.8, 32.7, 31.2, 30.9, 27.4, 25.9, 24.0, 23.9; HRMS (TOF, ES+) 
C17H32NO3S [M+H]+ calc'd 330.2103, found 330.2104.  
 
General Procedure for Alkene-Reduction. 
To a solution of sulfinamide (0.43 mmol) in EtOH (7 mL) was added Pd/C (45.6 mg, 
0.43 mmol). The reaction mixture was purged and back filled with H2 gas. The mixture 
was stirred at rt overnight. The mixture was filtered through celite pad and washed with 
CH2Cl2. Concentration in vacuo gave the crude product which was used without 
purification.  
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(R)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((R)-tert-butylsulfinyl)piperidine:  
[α]D
20 = -3.06 (c = 1.00, CHCl3);  1HNMR (400.1 MHz, CDCl3) δ (ppm): 4.52 (t, J = 5.2 
Hz, 1H), 4.09 (dd, J = 6.4, 4.4 Hz, 2H), 3.75 (t, J = 11.6 Hz, 2H), 3.19-3.26 (m, 2H), 3.04 
(m, 1H), 2.02-2.12 (m, 1H), 1.77-1.92 (m, 3H), 1.46-1.72 (m, 7H), 1.34 (d, J = 13.6 Hz, 
1H), 1.16 (s, 9H);  13C NMR (100.6 MHz, CDCl3) δ (ppm): 102.3, 67.1, 59.2, 58.5, 40.7, 
32.7, 29.0, 26.3, 25.9, 25.7, 23.7, 19.6; HRMS (TOF, ES+) C15H30NO3S [M+H]+ calc'd 
304.1946, found 304.1946. 
 
N
O
O
S
O
 
(S)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((R)-tert-butylsulfinyl)azepane:  
[α]D
20 = -1.7 (c = 0.33, CHCl3);  1HNMR (400.1 MHz, CDCl3) δ (ppm): 4.52 (t, J = 5.2 
Hz, 1H), 4.10 (dd, J = 6.8, 4.8 Hz, 2H), 3.75 (t, J = 12.0 Hz, 2H), 3.48 (q, J = 6.0 Hz, 
1H), 3.37 (m, 1H), 3.08 (m, 1H), 2.05 (m, 1H), 1.82-1.89 (m, 2H), 1.77 (m, 1H), 1.45-
1.65 (m, 9H), 1.33 (d, J = 13.6 Hz, 1H), 1.21 (s, 9H);  13C NMR (100.6 MHz, CDCl3) δ 
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(ppm): 101.5, 66.3, 60.8, 57.7, 42.3, 33.3, 32.1, 29.7, 27.6, 27.1, 25.3, 23.9, 23.5; HRMS 
(TOF, ES+) C16H32NO3S [M+H]+ calc'd 318.2103, found 318.2101. 
N
O
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(R)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((R)-tert-butylsulfinyl)azocane:  
[α]D
20 = -16.9 (c = 0.34, CHCl3); 1HNMR (400.1 MHz, CDCl3) δ (ppm): 4.51 (t, J = 5.2 
Hz, 1H), 4.08 (m, 2H), 3.75 (tt, J = 12.0, 2.4 Hz, 2H), 3.31-3.38 (m, 2H), 3.14-3.25 (m, 
2H), 2.01-2.12 (m, 1H), 1.81-1.89 (m, 2H), 1.57-1.74 (m, 8H), 1.52 (m, 1H), 1.30-1.44 
(m, 3H), 1.2 (s, 9H);  13C NMR (100.6 MHz, CDCl3) δ (ppm): 102.3, 67.0, 59.7, 58.6, 
43.5, 33.1, 32.8, 29.2, 28.9, 28.6, 25.9, 25.0, 24.1, 22.9; HRMS (TOF, ES+) C17H34NO3S 
[M+H]+ calc'd 332.2259, found 332.2257. 
 
General Procedure for Ring Closure. 
To the crude product cooled to 0 oC was added 5 ml of 95:5 TFA/H2O, after stirring at rt 
for 1 h the mixture was concentrated in vacuo to remove the TFA /H2O solvent. The 
residue was dissolved in DCE and PS-NaBH(OAc)3 (0.5 g, 1.08 mmol) was added and 
placed on a shaker overnight. The beads were filterd off and the solvent was concentrated 
in vacuo to give the crude azabicyclic product. Purification by flash chromatography 
gave the desired azabicylic ring product. 
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(S)-octahydroindolizine  
(S)-octahydroindolizine (1.7).  
Flash chromatography (9:1:0.5 CH2Cl2/MeOH/NH3) yield the product 10.1 mg (81% 
over 2-steps) as a yellow oil: [α]D20 = + 1.9 (c = 1.14, EtOH);  1H NMR (400.1 MHz, 
MeOD) δ (ppm):  4.44 (dt, J= 2, 4 Hz, 1H), 3.61, m, 1H), 3.37 (m, 1H), 3.12 (m, 1H), 
2.98 (t, J= 12.6 Hz, 1H), 2.04 (m, 1H), 1.89-1.39 (m, 9H); 13C NMR (100.6 MHz, 
MeOD) δ (ppm): 62.2, 58.2, 45.9, 31.8, 29.8, 28.9, 23.5, 23.1;  HRMS (TOF, ES+) 
C8H16N [M+H]+ calc'd 126.1277, found 126.1276. 
N
H
TFA  
(S)-octahydro-1H-pyrrolo[1,2-a]azepine (1.14).  
Flash chromatography (9:1:0.5 CH2Cl2/MeOH/NH3) yield the product 11.9 mg (86% 
over 2-steps) as off white solid: [α]D23 = +0.6 (c = + 1.55, EtOH); 1H NMR (400.1 MHz, 
MeOD) δ (ppm):  4.57 (s, 1H), 3.60 (m, 2H), 3.23 (m, 1H), 3.17 (m, 1H), 2.05-1.59 (m, 
12H);  13C NMR (100.6 MHz, MeOD) δ (ppm): 62.21, 60.41, 46.51, 32.29, 31.83, 29.46, 
27.57, 26.13, 25.74; HRMS (TOF, ES+) C14H18O4 [M+H]+ calc'd 140.1439, found 
140.1439. 
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(S)-decahydropyrrolo[1,2-a]azocine (1.20).  
Flash chromatography (9:1:0.5 CH2Cl2/MeOH/NH3) yield the product 13.3 mg (87% 
over 2-steps) as off white solid: [α]D20 = + 1.1 (c = 1.85, EtOH);  1H NMR (400.1 MHz, 
MeOD) δ (ppm):  3.62 (m, 2H), 3.34 (m, 1H), 3.18 (m, 2H), 1.6-2.0 (m, 14H);  13C NMR 
(100.6 MHz, CDCl3) δ (ppm): 60.7, 57.4, 44.2, 30.8, 28.1, 27.9, 24.6, 24.1, 24.0, 23.2;  
HRMS (TOF, ES+) C10H20N [M+H]+ calc'd 154.1596, found 154.1594. 
 
NS
O
MeO2C  
(S)-methyl 4-((tert-butylsulfinyl)imino)butanoate (1.22).  
To a solution of methyl 4-oxobutanoate (10 g, 86.2 mmol) in CH2Cl2 (500 mL) was 
added (S)-2-methylpropane-2-sulfinamide (12.9 g, 106.2 mmol) and CuSO4 (54.7 g, 
344.0 mmol). The reaction mixture was stirred at rt overnight. The mixture was filtered 
through a pad of celite and washed with CH2Cl2. Concentration in vacuo gave the crude 
product which was purified by automated flash chromatography (4:1 to 1:1 Hex/EtOAc) 
to yield the desired product 17.9 g (95%) as yellow oil: [α]D20 = +178.1 (c = 1.67, 
CHCl3); 1H NMR (400.1 MHz, CDCl3) δ (ppm): 8.13 (t, J = 2.8 Hz, 1H), 3.68 (s, 3H), 
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2.82-2.94 (m, 2H), 2.70-2.82 (m, 1H), 2.59-2.67 (m, 1H), 1.17 (s, 9H);  13C NMR (100.6 
MHz, CDCl3) δ (ppm): 172.4, 167.3, 56.9, 51.9, 31.2, 29.2, 22.4; HRMS (TOF, ES+) 
C9H18NO3S [M+H]+ calc'd 220.1007, found 220.1007. 
 
N
H
CO2Me
S
O
 
(S)-methyl-4-((S)-1,1-dimethylethylsulfinamido)hept-6-enoate (1.23).  
In-Mediated allylation were done according to procedures previously shown. The 
reaction was run on a 50 mmol scale, to afford the crude product as >19:1 dr, which was 
then purified by  flash chromatography (1:1 Hex/EtOAc) to yield the allylation product 
11.5 g (88%) as yellow oil: [α]D20 = +45.7 (c = 0.95, CHCl3); 1H NMR (400.1 MHz, 
CDCl3) δ (ppm): 5.78 (m, 1H), 5.15 (m, 2H), 3.67 (s, 3H), 3.40 (m, 1H), 3.22 (d, J= 7.2 
Hz, 1H), 2.40 (m, 3H), 1.90 (m, 1H), 1.75 (m, 1H), 1.20 (s, 9H);  13C NMR (100.6 MHz, 
CDCl3) δ (ppm): 173.9, 133.6, 119.6, 56.1, 55.1, 51.9, 40.1, 30.5, 30.1, 22.8; HRMS 
(TOF, ES+) C12H24NO3S [M+H]+ calc'd 262.1477, found 262.1476. 
H
N H
O
 
(S)-5-allylpyrrolidin-2-one (1.24).  
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To a solution of compound 1.23 (2.61 g, 10 mmol) in methanol (100 mL) was added 10 
mL of 12 N HCl aqueous solution at room temperature. The resultant mixture was then 
stirred at rt for 2 h. After concentrated, the residue was dissolved in 150 mL 
CH2Cl2 and 200 mL of saturated aqueous Na2CO3 was added. After overnight, the 
mixture is extracted with CH2Cl2; combined organic extracts were washed with water and 
brine and dried over Na2SO4. Filtration and concentration afforded the crude product, 
which was purified by flash chromatography (1:1 Hex/EtOAc) to yield the desired 
product 1.21 g (97%) as brown oil: [α]D20 = +2.5 (c = 1.16, CHCl3); 1H NMR (400.1 
MHz, CDCl3) δ (ppm); 6.43 (br s, 1H), 5.74 (m, 1H), 5.11 (d, J = 12.7 Hz, 2H), 3.70 (q, J 
= 6.5 Hz, 1H), 2.32 (m, 2H), 2.22 (m, 3H), 1.76 (m, 1H); 13C NMR (100.6 MHz, CDCl3) 
δ (ppm): 173.4, 153.5, 146.9, 130.5, 125.5, 125.2, 116.6, 113.9, 111.9, 60.6, 55.7, 34.1, 
28.6, 14.2; HRMS (TOF, ES+) C7H12NO [M+H]+ calc'd 126.0919, found 126.0921. 
 
General Procedure for lactam N-alkylation: 
To a solution of lactam (1 equiv), in DMF at 0 oC was added NaH (1.02 equiv) and the 
mixture was stirred for 10 mins and additional 10 mins at rt. At 0 oC bromide (1.5 equiv.) 
was then added slowly to the mixture and the reaction was warmed to rt and stirred for 2 
hrs.  The reaction was quenched with water and extracted with EtOAc (3x).  The 
combined organic extract was the dried over Na2SO4. Filtration and concentration 
afforded the crude product, which was purified by flash chromatography (1:1 
Hex/EtOAc).  
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N H
O
 
(S)-1,5-diallylpyrrolidin-2-one.  
The product was prepared according to the general procedure using allyl bromide. The 
reaction was run on a 5 mmol scale, to afford the product as a light brown oil (800.3 mg, 
97%): [α]D
20 = -21.4 (c = 0.44, CHCl3); 1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.70 (m, 
2H), 5.17 (m, 4H), 4.33 (dd, J = 10.4, 5.2 Hz, 1H), 3.67 (septet,  J = 4.0 Hz, 1H), 3.55 
(dd, J = 7.2 Hz, 1H), 2.8-2.47 (m, 3H), 2.05-2.23 (m, 2H), 1.77 (m, 1H);  13C NMR 
(100.6 MHz, CDCl3) δ (ppm): 175.03, 132.93, 132.89, 56.79, 43.25, 37.48, 30.18, 23.43; 
HRMS (TOF, ES+) C10H15NO [M+H]+ calc'd 166.1228, found 166.1223. 
 
N H
O
 
(S)-5-allyl-1-(but-3-en-1-yl)pyrrolidin-2-one.  
The product was prepared according to the general procedure using 4-bromobut-1-ene. 
The reaction was run on a 5 mmol scale, to afford the product as colorless oil (868.2 mg, 
97%): [α]D
20 = -26.3 (c = 0.73, CHCl3); 1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.66-
5.82 (m, 2H), 5.03-5.18 (m, 4H), 3.66-3.80 (m, 2H), 2.97 (m, 1H), 2.18-2.57 (m, 7H), 
1.69-1.78 (m, 1H);  13C NMR (100.6 MHz, CDCl3) δ (ppm): 175.3, 135.3, 132.9, 118.9, 
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117.0, 57.0, 39.7, 37.6, 31.9, 30.3, 23.6; HRMS (TOF, ES+) C11H18NO [M+H]+ calc'd 
180.1388, found 180.1387. 
 
N H
O
 
(S)-5-allyl-1-(pent-4-en-1-yl)pyrrolidin-2-one. 
 The product was prepared according to the general procedure using 5-bromopent-1-ene. 
The reaction was run on a 5 mmol scale, to afford the product as colorless oil (916.8 mg, 
95%): [α]D
20 = -25.3 (c = 0.84, CHCl3); 1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.65-
5.86 (m, 2H), 4.97-5.17 (m, 4H), 3.61-3.69 (m, 2H), 2.93 (m, 1H), 2.22-2.44 (m, 3H), 
2.10-2.20 (m, 1H), 2.07 (m, 3H), 1.55-1.79 (m, 3H);  13C NMR (100.6 MHz, CDCl3) δ 
(ppm): 175.2, 137.8, 132.9, 118.9, 115.3, 57.0, 40.0, 37.7, 31.3, 30.3, 26.7, 23.6; HRMS 
(TOF, ES+) C12H19NO [M+H]+ calc'd 194.2931, found 194.2929. 
 
 
General Procedure for ring closing metathesis of N-alkyl lactam: 
To a solution of N-alkyl-lactam (1 equiv), in CH2Cl2 was added 2nd Gen. Grubbs (0.05 
equiv). The mixture was refluxed for 1 – 2 h and concentrated. The resulting crude 
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product was purified by automated flash chromatography (1:1 Hex/EtOAc) to yield the 
desired product. 
 
N
H
O  
(S)-1,2,8,8a-tetrahydroindolizin-3(5H)-one (1.26).  
The product was prepared according to the general procedure. The reaction was run on a 
3 mmol scale, to afford the product as a brown oil (316.5 mg, 77%): [α]D
20 = -27.3 (c = 
0.62, CHCl3); 1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.78 (m, 1H), 5.69 (m, 1H), 4.24 
(dd, J = 16.0, 2.5 Hz, 1H), 3.55 (m, 2H), 2.25-2.42 (m, 4H), 1.99 (m, 2H), 1.68 (m, 1H); 
13C NMR (100.6 MHz, CDCl3) δ (ppm): 174.4, 124.3, 123.6, 53.1, 40.5, 32.6, 30.1, 25.7; 
HRMS (TOF, ES+) C8H12NO [M+H]+ calc'd 138.0919, found 138.0916. 
N
O
H
 
(S)-5,6,9,9a-tetrahydro-1H-pyrrolo[1,2-a]azepin-3(2H)-one (1.27).  
The product was prepared according to the general procedure. The reaction was run on a 
3 mmol scale, to afford the product as colorless oil (339.8 mg, 75%): [α]D20 = -22.3 (c = 
0.52, CHCl3); 1H NMR (400.1 MHz, MeOD) δ (ppm):  5.89 (m,1H), 5.80 (m, 1H), 3.81 
(m, 2H), 3.08 (dt, J = 1.6, 8 Hz, 1H), 2.4-2.2 (m, 7H), 1.66 (m, 1H);  13C NMR (100.6 
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MHz, CDCl3) δ (ppm):176.89, 132.37, 129.76, 60.49, 42.61, 36.90, 31.34, 28.61, 26.48; 
HRMS (TOF, ES+) C9H14NO [M+H]+ calc'd 152.1119, found 152.1116. 
 
N
H
O  
(S)-1,2,6,7,10,10a-hexahydropyrrolo[1,2-a]azocin-3(5H)-one (1.28).  
The product was prepared according to the general procedure. The reaction was run on a 
3 mmol scale, to afford the product as colorless oil (252.5 mg, 51%): [α]D
20 = -20.8 (c = 
0.42, CHCl3); 1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.81 (m, 1H), 5.71 (m, 1H), 3.81 
(dt, J = 13.6, 4.0 Hz, 1H), 3.58 (septet, J = 4.8  Hz, 1H), 2.74 (m, 1H), 2.34-2.45 (m, 2H), 
2.21-2.32 (m, 2H), 2.11-2.20 (m, 2H), 1.97-2.10 (m, 2H), 1.64-1.76 (m, 1H), 1.48-1.52 
(m, 1H);  13C NMR (100.6 MHz, CDCl3) δ (ppm): 175.9, 133.4, 125.8, 61.6, 42.9, 33.1, 
30.5, 26.9, 24.6, 24.5; HRMS (TOF, ES+) C10H16NO [M+H]+ calc'd 166.1232, found 
166.1233. 
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CHAPTER II 
 
TOTAL SYNTHESIS OF THE PYRROLIZIDINE CONTAINING NATURAL 
PRODUCT CREMASTRINE AND AN UNNATURAL ANALOGUE AND 
BIOLOGICAL EVALUATION AGAINST THE MUSCARINIC 
ACETYLCHOLINE RECEPTORS 
 
2.1 Introduction 
The azabicyclic ring system is a common structural subunit present in numerous 
alkaloid natural products and serves as an important scaffold in biologically active and 
pharmaceutically significant compounds.1,2,3,4 Pyrrolizidine, indolizidine, pyrrolo[1,2-
a]azepine, and pyrrolo[1,2-a]azocine are common examples of the azabicyclic ring 
system (Figure 2.1). Due to the importance of this ring system, much attention from the 
scientific community has been given to the synthesis of the azabicyclic skeleton. As 
previously shown, our lab has developed a robust and versatile methodology to access a 
variety of azabicyclic ring systems and azabicyclic lactams. The first total synthesis of 
cremastrine, a pyrrolizidine containing alkaloid, will highlight the usefulness and 
versatility of our methodology. 
 
N
pyrrolo[1,2-a]azepine
N N
pyrrolo[1,2-a]azocineindolizidine
N
pyrrolizidine  
Figure 2.1  Azabicyclic Ring Systems 
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2.2 Approach to Azabicyclic Ring Systems Via Chiral Sulfinamides  
Inspired by Ellman’s synthesis of chiral 2-substituted pyrrolidines that proceeds 
with high yields and diastereoselectivity (Scheme 2.1)5, we have developed a protocol to 
afford enantiopure azabicyclic ring systems.  
 
S
O
N
H
R1
R2O
OR2
MgBr
S
O
N
H
R1
OR2
OR2
95:5 TFA:H2O
10 min
Et3SiH, 24 h NH
R1
2.1 2.2 2.3  
Scheme 2.1 Synthesis of Chiral 2-Substituted Pyrrolidines 
 
 
Beginning with Ellman’s chiral N-sulfinylaldimine, an asymmetric Grignard 
addition or Indium-mediated allylation, N-alkylation, ring closing metathesis (RCM), and 
finally an intramolecular reductive amination or cyclization, reliably and efficiently 
produces enatiopure azabicyclic ring systems. This approach is outlined in Scheme 2.2. 
This methodology has been applied to the synthesis cremastrine, a pyrrolizidine alkaloid 
with reported activity against the muscarinic M3 receptor. 
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Scheme 2.2 Enantioenriched Azabicyclic Rings Via Chiral Sulfinamides 
 
2.3 Background of Cremastrine 
 Cremastrine, a pyrrolizidine alkaloid containing a C9 α-hydroxy ester (seen in 
Figure 2.2), was isolated from an ethanol extract of the Japanese tuber Cremastra 
appendiculata in 2005 by Ikeda and coworkers. This plant is widely used in traditional 
medicine in Japan and China for treatment of burns, frostbite, skin irritations, and 
snakebites. In an effort to investigate the biological properties of this herbal remedy, 
bioassay-guided chromatography resulted in the isolation of the pyrrolizidine natural 
product, cremastrine.6 
N
H
O
O
OH
Cremastrine
2.11
1
2
3
5
6
7
8
9
 
Figure 2.2 Cremastrine 
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 Cremastrine was tested for activity against the muscarinic receptors where it 
demonstrated notable inhibitory activity at the M3 receptor. Table 2.1 summarizes 
inhibition activities of cremastrine against all known muscarinic subtypes.6 The 
muscarinic acetylcholine receptor belongs to the G-protein coupled receptor super family 
and to date, five different subtypes have been individually cloned. The receptor can be 
activated by acetylcholine and muscarine, and in turn, its activation can be blocked by 
atropine. M2 and M4 receptor subtypes are coupled to the Gi family of G-proteins, 
whereas M1, M3, and M5 receptor subtypes couple to Gq family. Activation of the M3 
receptor is responsible for the increase of phosphatidyl inositol hydrolysis and calcium 
mobilization from the extracellular environment to the intracellular environment. The M3 
receptor is involved in a number of essential biological functions including 
neurotransmitter release, thermoregulation, smooth muscle contractions, gland secretion, 
cardiovascular activity, and meiosis. Due to its wide range of functions throughout the 
body, development of a highly selective agonist or antagonist could have a number of 
therapeutic applications. Such a ligand could be utilized in the treatment of irritable 
bowel syndrome, chronic obstructive pulmonary disease, and urinary tract disorders. To 
date, there is no highly selective agonist or antagonist of the M3 receptor. 7 
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Muscarinic 
Receptor 
Ki (nM) 
M1 505 
M2 >5517 
M3 126 
M4 498 
M5 1220 
Table 2.1 KiValues of Cremastrine to Muscarinic Receptors, M1-5 
 Tropanes are an example of alkaloid compounds that act as muscarinic 
acetylcholine receptor antagonists.8 A number of biologically active nortropanes are 
shown Figure 2.3. Topologically, similarities exist between cremastrine and this scaffold, 
including a tertiary amine, a small aza-ring functionality, and an ester linkage from the 
aza-cyclic skeleton.  
 
N
H O
O
OH
N
N
O O
O
N
O
O
N
O
O
O OH
OMeO
O
N
O
O
OH
OH OH
atr
opi
ne
scopolamine cocaine
crema
strine
D-hyoscyamine L-hyoscyamine
 
Figure 2.3 Topological Similarities Between Cremastrine and Tropane Derivatives 
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2.4 Other Approaches to the Pyrrolizidine Core 
 Due to the unique biological properties and promising applications of 
pyrrolizidine natural products, a variety of synthetic routes have been devised to access 
the pyrrolizidine core structure of a variety of natural products.9 Two synthetic routes 
stand out in the literature: the total synthesis of epohelmin B by Fürstner and coworkers9c 
and the total synthesis of (-)-trachelanthamidine by Ishibashi and coworkers9d.  
 Fürstner’s approach (seen in scheme 2.3) uses an azonia-Cope rearrangement to 
set the chiral amine stereocenter with excellent optical purity and a nosyl 
deprotection/transannular-epoxide-opening cascade to access the pyrrolizidine core of the 
natural product.9c Azonia-Cope rearrangement methodology by Kobayashi and coworkers  
allowed for the transformation of aldehyde 2.12 to chiral homoallylic amine. This 
proceeded through a [3,3]-sigmatropic rearrangement to form homoallylic amine 2.13 
after hydrolytic workup. A number of synthetic steps later they arrived at azacyclooctene 
derivative 2.16, which upon treatment with mercaptoacetic acid initiates a transannular-
epoixde-opening cascade reaction by exposing the secondary amine and spontaneously 
opening the oxirane to provide pyrrolizidine derivative 2.17. One more synthetic 
transformation afforded the pyrrolizidine natural product, epohelmin B 2.18, in 28% yield 
in 11 steps from commercially available starting materials. 
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Scheme 2.3 Total Synthesis of Epohelmin B 
 
  Ishibashi and coworkers synthesized (-)-trachelanthamidine through a key single 
electron transfer step using 1,4-dimethylpiperazine to access the substituted pyrrolizidine 
ring (Scheme 2.4).  Compound 2.21, 2-(2-acetoxyethenyl)-N-(trichloroacetyl)pyrrolidine, 
was accessed from proline after a number of synthetic steps. Refluxing this 
trichloroacetyl in 1,4-dimethylpiperazine allowed for a radical cyclization reaction to 
furnish the pyrrolizidine core. This radical cyclization proceeds through a single electron 
transfer reaction from 1,4-dimethylpiperazine to eliminate a chloride anion and provide a 
radical intermediate. This radical species can then undergo an intramolecular termination 
step to form the substituted pyrrolizidine core as a single stereoisomer. Elucidation of the 
mechanism of this single electron transfer reaction is currently being explored by 
Ishibashi and coworkers. With pyrrolizidine 2.22, two more synthetic transformations 
yielded (-)-trachelanthamidine 2.23 in 13% yield over 9 steps.9d 
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Scheme 2.4  Total synthesis of (-)-Trachelanthamidine  
 
 
2.5 Total Synthesis of Cremastrine 
 Our retrosynthetic analysis sought to incorporate methodology developed in the 
Lindsley laboratory that allows for rapid and efficient access to the azabicyclic ring 
structure. Scheme 2.5 outlines our retrosynthesis of cremastrine 2.11. An initial 
disconnection at the C9 ester linkage yields α-hydroxy carboxylic acid 2.24 and C9 
hydroxy pyrrolizidine 2.23 where, in the synthetic direction, cremastrine can be accessed 
through a carbodiimide coupling of the alcohol and carboxylic acid. The pyrrolizidine 
core 2.23 could be accessed through pyrrolidine derivative 2.25 which is prepared from 
sulfinamide 2.26 after several steps. The chiral sulfinamide is constructed through an 
indium mediated addition of aldimine 2.27 and (E)-bromobutene derivative 2.28. The 
tert-butyldimethylsilyl (TBS) protected α-hydroxy carboxylic acid can be accessed from 
the amino acid, D-isoleucine 2.29. 
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Scheme 2.5 Retrosynthesis of Cremastrine 
  
 Construction of TBS protected α-hydroxy carboxylic acid is outline in Scheme 
1.6 below. Conversion of D-isoleucine 2.30 to α-hydroxy carboxylic acid 2.31 was 
accomplished using a procedure that converts the amino acid to the α-hydroxy acid with 
retention of stereochemistry. Treatment of the amino acid with aqueous nitrous acid leads 
to diazotization of the α amine stereocenter followed by hydrolysis to furnish the 
enatiopure α-hydroxy acid 2.31.10 Treatment of acid 2.31 with excess tert-
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butyldimethylsilyl chloride, followed by basic hydrolysis, gives compound 2.32 in 65% 
yield over 3 steps.11  
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Scheme 2.6  Synthesis of α-Hydroxy Carboxylic Acid 2.32 
 
 For the generation of the pyrrolizidine core (see Scheme 2.7), we initially began 
with acetal 2.32. Displacement of the bromide with sodium cyanide yielded the nitrile 
which was reduced to the aldehyde 2.34 using diisobutylaluminium hydride.12 Another 
approach to aldehyde 2.34, which did not generate cyanide waste, began with 4-pentenal 
(2.33). Conversion of aldehyde 2.33 to the acetal, followed by oxidative cleavage with 
ozone and dimethyl sulfide, generated aldehyde 2.34. A condensation of commercially 
available (R)-tert-butanesulfinamide and aldehyde 2.34 gives chiral aldimine 2.35.  
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Scheme 2.7 Synthesis of N-sulfinylaldimine 2.35 
 
 
From aldimine 2.35, we next sought to install two stereocenters through an 
indium mediated allylation using a variety of bromides. These results are outlined in 
Scheme 2.8. Utilizing bromo-ester 2.36 and 2.37 gave the desired homoallylic 
sulfinamide 2.41 and 2.42 in 50-55% conversions, respectively. These results were 
promising as revealed by the bromo-esters. Using free alcohol 2.40 led to lower 
conversion and diastereoselectivity, while no reaction occurred when PMB-ether 2.39 
was used. An increase of the reaction conversion to product and moderate 
diastereoselectivity was observed when TBS-ether 2.38 was used (>85% conversion, 
>4:1 d.r.) (Scheme 2.8).  
44 
 
BrR
Indium
Sat. NaBr
rt, 48 h 2.26, 2.41 - 2.44
conv
(%)Bromide
CO2Me
CO2Et
CH2OTBS
CH2OPMB
CH2OH
2.41
2.42
2.26
2.43
2.44
2.36
2.37
2.38
2.39
2.40
Sulfinamide
55
50
 >85
0
31
R
>6:1
>6:1
>4:1
-
3:1
dr
[In]
N
S
OHR
O
O
N
H
S
O
2.35
O
O
NH
S
O
R
O O
 
Scheme 2.8 Indium-Mediated Allylation Aldimine 2.35 
 
The syn-configuration was assigned according to literature precedent and the six-
membered chair Zimmerman-Traxler transition state model.13 These reactions were all 
performed at 0.05 mmol scale of 2.35. Surprisingly, upon scaling up the synthesis (even 
at 0.25 mmol scale of 2.35) only 20% conversion to the desired product was observed. 
After surveying a variety of reaction conditions, we found that pre-mixing by stirring and 
sonication of the indium metal and bromide before adding the aldimine was crucial to 
deliver homoallylic sulfinamide 2.26 with yields consistent to the small-scale reactions.  
With sulfinamide 2.26 in hand, next we sought to access the pyrrolizidine core 
structure 2.23. Scheme 2.9 below outlines the synthetic approach. Hydroboration-
oxidation of the terminal olefin of 2.26 furnished primary alcohol 2.45 in excellent yield. 
Initial attempts to form the substituted pyrrolidine ring system involved mesylation of the 
alcohol and displacement in a 5-exo-tet cyclization fashion. This was unfortunately 
unsuccessful, but under Mitsunobu conditions, we successfully obtained substituted 
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pyrrolidine 2.25. NOESY-NMR data confirms the syn-stereochemical relationship of the 
two chiral centers on the pyrrolidine ring. From here, TBAF deprotection of the tert-
butyldimethylsilyl ether gave primary alcohol 2.46. Deprotection of the acetal and the 
sulfinyl exposed the aldehyde and amine, respectively. This was theorized to undergo an 
intramolecular condensation to form the imine, upon which an addition of a reducing 
agent would produce 2.23, the pyrrolizidine core structure. A screening of conditions 
outlined in Scheme 1.9 resulted in no formation of any desired product. These conditions 
were based around work by Ellman and coworker’s5 and by the Lindsley laboratory.14 
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Scheme 2.9 Attempted Formation of the Pyrrolizidine Core Structure 
  
 We believe that the free alcohol underwent undesired side reactions that 
prevented the formation of 2.23 from substituted pyrrolidine 2.46. The formation of the 
ester side chain of cremastrine would remove this alcohol from the ring closing reaction. 
Thus, we next sought to form the ester linkage through a carbodiimide coupling of 
primary alcohol 2.46 and carboxylic acid 2.24. Scheme 2.10 outlines this approach. A 1-
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ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC·HCl) mediated 
coupling between acid 2.24 and alcohol 2.46 gave ester 2.47 in excellent yield. Upon 
screening the same set of conditions previously used for the attempted transformation of 
2.46 to 2.23, the best deprotection/reductive amination conditions were found to be 
TFA:H2O (95:5) followed by triethylsilane as the reducing agent. Global deprotection of 
2.47 allowed for intramolecular condensation to the imine pyrrolizidine 2.48, then 
reductive amination with triethyl silane furnished the natural product cremastrine 2.11 in 
80% yield from ester 2.47. 
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Scheme 2.10 Completion of the synthesis of cremastrine 
 
 
 Employing conditions developed in the Lindsley laboratory to access azabicyclic 
scaffolds, the total synthesis of cremastrine was completed. Starting from commercially 
available aldehyde 2.34, cremastrine was synthesized in a longest linear sequence of 7 
steps (9 steps overall) with a 31% overall yield. Additionally, an unnatural analogue, 
benzylated at the α-hydroxy ester linkage was generated from primary alcohol 2.46 using 
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similar chemistry to access cremastrine. Scheme 2.11 outlines the chemistry to this 
unnatural analogue 
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Scheme 2.11 Synthetic Route to an Unnatural Analogue of Cremastrine 
  
Cremastrine was reported to display modest selectivity for the binding the the 
muscarininc acetylcholine receptor subtype 3 (2 to 20 fold), were upon evaluation by our 
lab of the natural and unnatural analogue against muscarinic acetylcholine receptor 
subtype 1-5 (M1-M5) in a functional assay to determine if the modest M3 selectivity 
reported by Ikeda would translate into selective M3 functional antagonist activity. It was 
shown that cremastrine was a pan-mAChR functional antagonist, which moderately 
inhibited M1-M5 (M1 IC50 = 2.8 μM, M2 IC50 = >10 μM, M3 IC50 >10 μM, M4 IC50 = >10 
μM, M5 IC50 = 4.0 μM). There was a clear preference for M1 and M5 and very weak 
activity at the M3, contrary data to that of the isolation paper. Thus, it can be concluded 
that cremastrine is not a selective M3 antagonist. The unnatural analog of cremastrine was 
more potent than the natural cremastrine (M1 IC50 = 1.9 μM, M2 IC50 = >10 μM, M3 IC50 
=5 μM, M4 IC50 = 5.2 μM, M5 IC50 = 2.0 μM), but is still a pan-mAChR antagonist. 
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2.6 Cremastrine Experimentals 
All reagents were purchased from Sigma-Aldrich Corp., TCI America, FCH Group 
Reagents for Synthesis, and Alfa Aesar and were used without purification. Analytical 
thin-layer chromatography (TLC) was performed on 250 μm silica gel plates from 
Sorbent Technologies.  Visualization was accomplished via UV light, and/or the use of 
iodine on silica and potassium permanganate solution followed by application of heat.  
Chromatography was performed using Silica Gel 60 (230-400 mesh) from Sorbent 
Technologies or Silica RediSep Rf flash columns on a CombiFlash Rf automated flash 
chromatography system.  All 1H and 13C NMR spectra were recorded on a Bruker AV-
400 (400 MHz) instrument or a Bruker AV-400 (500 MHz) instrument.  Chemical shifts 
are reported in ppm relative to residual solvent peaks as an internal standard set to δ 7.26 
and δ 77.00 (CDCl3).  Data are reported as follows:  chemical shift, multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, p = pentet br = broad, dd=doublet of doublets, 
dq=doublet of quartets, td = triplet of doublets, pd = pentet of doublets, m = multiplet), 
coupling constant (Hz), integration.  Low resolution mass spectra (LCMS) were obtained 
on an Agilent 1200 LCMS with electrospray ionization.  High resolution mass spectra 
(HRMS) were recorded on a Waters Qtof-API-US plus Acquity system with ES as the 
ion source.  Analytical high pressure liquid chromatography (HPLC) was performed on 
an Agilent 1200 analytical LCMS with UV detection at 214 nm and 254 nm along with 
ELSD detection.  Optical rotations were acquired on a Jasco P-2000 polarimeter at 23 oC 
and 589nm.  The specific rotations were calculated according to the equation [α]
23
𝐷
 = 100𝛼
𝑙 𝑥 𝑐  
where l is the path length in decimeters and c is the concentration in g/100mL. 
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(R)-N-(3-(1,3-dioxan-2-yl)propylidene)-2-methylpropane-2-sulfinamide (2.35).   
To a solution of 3-(1,3-dioxan-2-yl)propanal (2.1 g, 14.6 mmol) in CH2Cl2 (100 mL) was 
added (R)-2-methylpropane-2-sulfinamide (2.12 g, 17.5 mmol) and CuSO4 (7.0 g, 43.8 
mmol). The reaction mixture was stirred at rt overnight. The mixture was filtered through 
a through celite pad and washed with CH2Cl2. Concentration in vacuo gave the crude 
product which was purified by automated flash chromatography (4:1 to 1:1 Hex/EtOAc) 
to yield the desired product (3.35 g, 93%) as yellow oil: [α]D20 = -208.8 (c = 0.86, 
CHCl3); 1H NMR (400.1 MHz, CDCl3) δ (ppm): 7.98 (t, J = 4.10 Hz, 7.36 Hz, 1H), 4.50 
(t, J = 4.8 Hz, 1H), 3.97 (dd, J = 6.0, 4.8 Hz, 2H), 3.62 (dt, J = 2.25 Hz, 12.60 Hz, 2H), 
2.52 (dt, J = 4.0 Hz, 2H), 1.93 (m, 1H), 1.81 (m, 2H), 1.23 (dm, J = 13.8 Hz, 1H), 1.07 (s, 
9H); 13C NMR (100.6 MHz, CDCl3) δ (ppm): 168.69, 100.58, 66.57, 56.28, 30.40, 
30.28, 25.45, 22.05; HRMS (TOF, ES+) C11H22NO3S [M+H]+ calc'd 248.1320, found 
248.1319. 
 
(R)-N-((3S,4S)-4-(((tert-butyldimethylsilyl)oxy)methyl)-1-(1,3-dioxan-2-yl)hex-5-en-
3-yl)-2-methylpropane-2-sulfinamide (2.26).  
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To a solution of (E)-((4-bromobut-2-en-1-yl)oxy)(tert-butyl)dimethylsilane (10.28 g, 
38.739 mmol) dissolved in a 9.3:10 solution of NaBr and H2O (14 g:15 mL) was added 
indium powder (4.431 g, 38.739 mmol). This solution was stirred vigorously for 1 hour 
followed by sonication for another 1hr, upon which (R)-N-((3S,4S)-4-(((tert-
butyldimethylsilyl)oxy)methyl)-1-(1,3-dioxan-2-yl)hex-5-en-3-yl)-2-methylpropane-2-
sulfinamide was added. This solution stirred at rt for 48 hours, quenched with sat. 
NaHCO3 and filtered through a bed of celite. Phases were separated and the aqueous 
phase was extracted with CH2Cl2. All organic layers were combined, washed with H2O, 
dried my MgSO4, filtered, and concentrated in vacuo. Crude product was purified by 
flash column chromatography (7:3 Hexanes:EtOAc) to give the desired product (3.57 g, 
85 % yield, 4:1). [α]D20 = -23.2 (c = 1.0, CHCl3); 1H NMR (400.1 MHz, CDCl3) δ 
(ppm): 5.74 – 5.61 (m, 1H), 5.26 – 5.07 (m, 2H), 4.47 (t, J = 4.89, 1H), 4.09 – 4.04 (m, 
2H), 3.80 – 3.62 (m, 5H), 3.45 – 3.37 (m, 1H), 2.71 – 2.63 (m, 1H), 2.11 – 1.99 (m, 1H), 
1.89 – 1.51 (m, 4H), 1.33 – 1.29 (d, J = 15, 1H), 1.17 (s, 9H), 0.87 (s, 9H), 0.04 (s, 3H), 
0.03 (s, 3H). 13C NMR (100.6 MHz, CDCl3) δ (ppm): 135.0, 119.8, 102.1, 66.8, 64.2, 
58.0, 56.0, 51.5 31.8, 26.2, 25.8, 25.7, 22.8, 18.2, -5.3, -5.4; HRMS (TOF, ES+) 
C21H43NO4SSi [M+H]+ calc’d 434.2760, found 434.2762. 
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(R)-N-((3S,4S)-4-(((tert-butyldimethylsilyl)oxy)methyl)-1-(1,3-dioxan-2-yl)-6-
hydroxyhexan-3-yl)-2-methylpropane-2-sulfinamide (2.45).  
To a solution of (870 mg, 2.007 mmol) in 0.25 mL anhydrous THF at 0°C was added 9-
BBN (6 mL of 0.5M in THF). Stir for 4 hours at 0°C. Upon full consumption of starting 
material (TLC or LCMS), an excess of 30% H2O2:15% NaOH (1:1) (40ml total) was 
added slowly at 0°C. Stir for 16 hours and quench reaction with H2O, extract 4X with 
EtOAc (15 mL ea), dried with MgSO4, and filter through a bed of celite. Concentration in 
vacuo gave the crude product which was purified by flash chromatography (19:1 
CH2Cl2:MeOH to 9:1 CH2Cl2:MeOH). To yield desired alcohol as a colorless oil (887mg, 
98% yield). [α]D20 = -14.167 (c = 0.99, CHCl3); 1H NMR (400.1 MHz, CDCl3) δ (ppm): 
4.5 (t, J = 4.75, 1H), 4.28 (d, J = 8.86, 1H), 4.09 – 4.05 (m, 2H), 3.79 – 3.64 – (m, 4H), 
3.57 – 3.53 (dd, J = 5.89, 1H), 3.22 ( m, 1H), 2.09 – 2.00 (m, 2H), 1.89 – 1.81 (m, 1H), 
1.77 – 1.71 (m, 1H), 1.61 – 1.42 (m, 5H), 1.32 (d, J = 13.2, 1H), 1.19 (s 9H), 0.88 (s, 
9H), 0.05 (s, 3H), 0.04 (s, 3H). ). 13C NMR (100.6 MHz, CDCl3) δ (ppm):102.0, 66.8, 
64.8, 61.5, 59.2, 56.0, 42.6, 32.3, 30.8, 27.7, 25.9, 25.7, 22.9, 18.3, -5.43, -5.46; HRMS 
(TOF, ES+) C21H46NO5SSi [M+H]+ calc’d 452.2866, found 452. 2869. 
 
(2S,3S)-2-(2-(1,3-dioxan-2-yl)ethyl)-3-(((tert-butyldimethylsilyl)oxy)methyl)-1-((S)-
tert-butylsulfinyl)pyrrolidine (2.25). 
N
SO
OTBSO
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 To a solution of (1.47 g, 3.26 mmol) in 32 mL THF at 0°C was added 1.9 mL of 
diethylazodicarboxylate (40% in toluene) (4.234 mmol) followed by triphenylphosphine 
(1.11 g 4.234 mmol). Reaction was monitored by TLC and stirred for 3 hours. Quench 
with 32 mL H2O and separate the organic and aqueous layer. Aqueous was extracted 3 
times with EtOAc (15 mL ea) and all organic layers were combined. Organic layer was 
dried with MgSO4, filtered through a bed of celite, and concentrated in vacuo. Crude 
product was purified by column chromatography (100% CH2Cl2 to 10:1 CH2Cl2:MeOH) 
to give the desired compound as a colorless oil (1.02 g, 72%).). [α]D20 = -35.3 (c = 1.12, 
CHCl3); 1H NMR (400.1 MHz, CDCl3) δ (ppm) = 4.49 (t, J = 5.02 Hz, 1H), 4.07 (dd, J = 
5.05, 2H), 3.73 (m, 2H), 3.62 (m, 1H), 3.52 (m, 1H), 3.43 (m, 2H), 2.72 (m, 1H), 2.02 (m, 
2H), 1.90 (m, 1H), 1.61 (m, 5H), 1.32 (d, J = 13 Hz, 1H), 1.18 (s, 9H), 0.87 (s, 9H), 0.03 
(s, 3H), 0.02 (s, 3H); 13C NMR (100.6 MHz, CDCl3) δ (ppm) = 102.10, 68.20, 66.83, 
63.93, 57.36, 45.32, 40.46, 31.33, 30.23, 28.83, 25.88, 25.75, 23.99, 18.18, -5.4,0-5.45; 
HRMS (TOF, ES+) C21H43NO4SSi [M+H]+ calc’d 434.2760, found 434.2761. 
 
 
((2S,3S)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((S)-tert-butylsulfinyl)pyrrolidin-3-
yl)methanol (2.46).  
N
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To a solution of (1.02 g, 2.35 mmol) in 25 mL THF at 0°C was added 3.0 mL of a 1.0 M 
solution of tetrabutylammonium fluoride dropwise. Allow to warm to RT and stir for 6 
hours. Quench with 25 mL H2O and extract 3 times with EtOAc (25 mL ea). Combine 
organic layers, dry with MgSO4, and filter through a bed of celite. Concentrate in vacuo 
and purify crude material by flash column chromatography (100% CH2Cl2 to 10:1 
CH2Cl2:MeOH) to give desired alcohol as a white solid (699 mg, 93% yield). ). [α]D20 = -
55.0 (c = 1.21, CHCl3); 1H NMR (400.1 MHz, CDCl3) δ (ppm) = 4.48 (t, J = 5.15 Hz, 
1H), 4.03 (dd, J = 4.85 Hz, 2H), 3.73 – 3.5 (m, 6 H), 2.79 (m, 1H), 2.28 (m, 1H), 2.0 (m, 
1H), 1.88 (m, 1H), 1.68 (m, 2H), 1.55 – 1.44 (m, 3H), 1.29 (d, J = 9.2, 1H), 1.14 (s, 9H); 
13C NMR (100.6 MHz, CDCl3) δ (ppm): 13C NMR (100.6 MHz, CDCl3) δ (ppm) = 
101.97, 68.01, 66.77, 61.37, 57.75, 44.52, 39.33, 32.10, 27.76, 25.63, 24.38, 24.03; 
HRMS (TOF, ES+) C15H29NO4S [M+H]+ calc’d 320.1896, found 320.1896. 
 
 
(2R,3R)-2-hydroxy-3-methylpentanoic acid (2.31).  
A solution of D-isoleucine (1.311 g, 10.00 mmol) was dissolved in 40 mL of 0.5M 
H2SO4 and cooled to 0°C. Sodium nitrite was next dissolved in 13.5 mL H2O and slowly 
added to the reaction flask. This solution stirred at 0°C for 3 hours and then at rt for 24 
hours. Extract 3 times with diethyl ether (50 mL ea), organic layers were combined, and 
then washed once with brine and once with H2O (15 mL ea). The organic phase was dried 
with Na2SO4, filtered, and concentrated in vacuo to give a viscous oil. Recrystallization 
HO
O
OH
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with hexane-ether produced carboxylic acid (1.13 g, 8.5 mmol). ). [α]D20 = -18.0 (c = 
0.75, CHCl3);  1H NMR (400.1 MHz, D2O) δ (ppm) = 4.18 (d, J = 3.5 Hz, 1H), 1.86 (m, 
1H), 1.48 – 1.38 (m, 1H), 1.29 – 1.18 (m, 1H), 0.98 (d, J = 7.3 Hz, 3H), 0.90 (t, J =7.2 
Hz, 3H). 13C NMR (100.6 MHz, CDCl3) δ (ppm): 179.1, 74.5, 38.6, 23.8, 15.0, 11.6; 
HRMS (TOF, ES+) C6H12O3Na [M+H]+ calc’d 155.0684, found 155.0683. 
 
 
(2R,3R)-2-((tert-butyldimethylsilyl)oxy)-3-methylpentanoic acid (2.32).  
To a cooled to 0°C solution of 1.25 (750 mg, 5.68 mmol) and imidazole (1.16 g, 17.03 
mmol) in anhydrous DMF was added tert-butyldimethylsilyl chloride (2.14 g, 14.19 
mmol). Reaction flask was removed from the ice bath and stirred at RT for 16 hours. The 
reaction was quenched with 100 mL H2O, extracted 3 times with diethyl ether (50 mL 
ea), organic layers were combined, and washed with brine and water (50 mL ea). Organic 
layer was dried with MgSO4, filtered through a bed of celite, and concentrate in vacuo. 
Crude was redissolved in 50 mL of MeOH and cooled to 0°C with an ice bath. K2CO3 (2 
g, 138.025 mmol) was dissolved in 15 mL H2O and slowly added to reaction flask. 
Reaction stirred for 4 hours at RT and subsequently concentrated in vacuo. Redissolve in 
20 mL H2O and acidify to pH=4 with 10% citric acid. Reaction was extracted 3 times 
with diethyl ether (40 mL ea), dry with Na2SO4, filtered through celite, and concentrated 
in vacuo. Crude oil was purified by column chromatography (5:1 hexanes: EtOAc) to 
give desired carboxylic acid (1.01 g, 4.37 mmol). 1H NMR (400.1 MHz, CDCl3) δ (ppm) 
HO
O
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= 4.14 (d, J = 4 Hz, 1 H), 1.8 (m, 1H), 1.5 (m, 1H), 1.27 (m, 1H), 0.97 – 0.83 (m, 16H), 
0.1 (s, 6H). 13C NMR (100.6 MHz, CDCl3) δ (ppm): 177.90, 76.68, 39.77, 25.64, 24.12, 
18.10, 15.10, 11.70, -5.06, -5.19.  HRMS (TOF, ES+) C6H26O3SiNa [M+H]+ calc’d 
269.1549, found 269.1548. 
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(2R,3R)-((2S,3S)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((S)-tert-butylsulfinyl)pyrrolidin-3-
yl)methyl-2-((tert-butyldimethylsilyl)oxy)-3-methylpentanoate (2.47).  
To a solution of alcohol (103 mg, 0.322 mmol) and acid (87 mg, 0.355 mmol) in 3.5 mL 
CH2Cl2 at 0°C was added 1 crystal of 4-dimethylaminopyridine followed by 1-Ethyl-3-
[3-dimethylaminopropyl]carbodiimide hydrochloride (135.8 mg, 0.71 mmol). Reaction 
was allowed to warm to rt.  Reaction was stirred to 2 hours, quenched with H2O, and 
extracted 3 times with diethyl ether (5 mL ea). Combine organic layers, dry with MgSO4, 
and filter through a bed of celite. Concentrate in vacuo and purify crude material by flash 
column chromatography (50:1 CH2Cl2:MeOH to 10:1 CH2Cl2:MeOH) to give desired 
ester 1.42 as a light yellow solid (169 mg, 96% yield). ). [α]D20 = -26.0 (c = 1.00, 
CHCl3); ). 1H NMR (400.1 MHz, CDCl3) δ (ppm) = 4.48 (t, J = 5.15 Hz, 1H), 4.11 – 4.04 
(m, 4H), 4.00 (d, J=5.43, 1H), 3.76 – 3.69 (m, 3H), 3.64 (q, J=8.5, 1H), 3.43 (m, 1H), 
2.84 – 2.74 (m, 2H), 2.47 (q, J = 5.1, 1H), 2.16 (q, J = 3.9, 1H), 2.11 – 1.94 (m, 2H), 1.82 
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– 1.71 (m, 2H), 1.69 (s, 1H), 1.66 – 1.41 (m, 5H), 1.32 (d, J = 13 Hz, 1H), 1.88 (s, 9H), 
0.90 (s, 9H), 0.89 (d, J = 7.3 Hz, 3H), 0.86 (t, J=7.6 Hz, 3H). 13C NMR (100.6 MHz, 
CDCl3) δ (ppm):173.45, 101.78, 76.33, 68.22, 67.80, 66.77, 57.83, 40.77, 39.39, 38.95, 
32.11, 28.07, 25.64, 24.58, 23.99, 23.92, 23.88, 18.16, 15.38, 11.41, -5.00, -5.46. HRMS 
(TOF, ES+) C27H53NO6SSi [M+H]+ calc’d 548.3441, found 548.3445. 
 
(2R,3R)-((1S,7aS)-hexahydro-1H-pyrrolizin-1-yl)methyl-2-hydroxy-3-
methylpentanoate (2.11).  
A solution of ester 15 (50 mg, 0.0914 mmol) in 2 mL of 95:5 trifluoroacetic acid:H2O 
was stirred for 1 hr at room temperature then 0.19 mL of triethyl silane was added. This 
solution was stirred over night and concentrated in vacuo to give a crude, yellow oil. This 
was dissolved in 1 mL DMSO and purified by reverse phase chromatography (2% to 45% 
H2O(0.1%TFA):AcCN) to give (19 mg, 80% yield) as a colorless oil. [α]D20 = -15.2 (c = 
0.97, CHCl3) 1H NMR (400.1 MHz, CDCl3) δ (ppm) = 6.87 (m, 1H), 4.49 (d, J = 5.2, 
1H), 4.33 (m, 1H), 4.20 (m, 1H), 4.18 (m, 1H), 3.55 (m, 1H), 3.49 (t, J = 7 Hz 1H), 2.88 
(m, 1H), 2.8 (m, 1H), 2.65 (dt, J = 8.1, 1H), 1.99 (m, 1H), 1.90 – 1.80 (br m, 4H), 1.72 
(m, 2H), 1.59 (m, 1H), 1.42 (m, 1H), 1.1 (d, J = 4 Hz, 3H), 0.99 (t, J = 7 Hz, 3H). 13C 
NMR (100.6 MHz, pyr-d5) δ (ppm): 174.6, 75.6, 68.1, 63.1, 55.38, 53.27, 39.9, 39.46, 
26.64, 26.2, 25.93, 24.78, 15.81, 11.75; HRMS (TOF, ES+) C14H26NO3 [M+H]+ calc’d 
256.1913, found 256. 1911. 
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(2R,3R)-2-(benzyloxy)-3-methylpentanoic acid (2.50) 
To a solution of carboxylic acid (180 mg, 1.347 mmol) in 13.8 mL of methanol was 
added 1 mL of trimethylsilyldiazomethane (2 M solution in diethyl ether) at 0°C. Allow 
to warm to rt and concentrate in vacuo to give a light yellow crude oil. The crude oil was 
then redissolved in 5 mL of CH2Cl2 followed by an addition of benzyl bromide (0.2 mL, 
1.684 mmol) then silver oxide (390.2 mg, 1.684 mmol). Reaction was stirred over night, 
filtered through a pad of celite, washed with CH2Cl2, and concentrated in vacuo to yield 
crude benzyl ether. Crude was redissolved in 5 mL of methanol followed and cooled to 
0°C. Next, 5 mL of a 0.28 M solution of potassium hydroxide was added dropwise and 
stirred for 1 hr. Aqueous solution was washed with ethyl acetate (2X, 5 mL ea), aqueous 
was acidified to PH=3, and aqueous was partitioned with diethyl ether (3X, 10 mL ea). 
All organic layers were combined, dried with MgSO4, concentrated in vacuo and purified 
by flash column chromatography (8:1 to 4:1 hexanes: ethyl acetate) to give of carboxylic 
acid (201 mg, 70%). [α]D20 = -29.2 (c = 1.12, CHCl3) 1H NMR (400.1 MHz, CDCl3) δ 
(ppm) = 7.27 – 7.30 (m, 5H), 4.74 (d, J = 11.3 Hz, 1H), 4.46 (d, J = 11.3 Hz, 1H), 3.85 
(d, J = 5.18 Hz, 1 H), 3.19 (m, 1H), 1.59 (m, 1H), 1.32 (m, 1H), 0.99 (d, J = 6.45 Hz, 
3H) 0.90 (t J = 7.45, 3H) 13C NMR (100.6 MHz, CDCl3) δ (ppm): 177.55, 137.16, 
128.40, 128.03, 127.97, 82.10, 72.88, 37.91, 24.48, 15.25, 11.40;  HRMS (TOF, ES+) 
C13H17O3Na [M+H]+ calc’d 244.1111, found 244.1113. 
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(2R,3R)-((2S,3S)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((S)-tert-butylsulfinyl)pyrrolidin-3-
yl)methyl 2-(benzyloxy)-3-methylpentanoate (2.51) 
To a solution of alcohol (81.23 mg, 0.2545 mmol) and (2R,3R)-2-(benzyloxy)-3-
methylpentanoic acid (59.4 mg, 0.2676 mmol) in 3.5 mL CH2Cl2 at 0°C was added 1 
crystal of 4-dimethylaminopyridine followed by 1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (194.65 mg, 1.018 mmol). Reaction 
was allowed to warm to rt.  Reaction was stirred to 2 hours, quenched with H2O, and 
extracted 3 times with diethyl ether (5 mL ea). Combine organic layers, dry with MgSO4, 
and filter through a bed of celite. Concentrate in vacuo and purify crude material by flash 
column chromatography (50:1 CH2Cl2:MeOH to 10:1 CH2Cl2:MeOH) to give desired 
ester as a light yellow solid (125 mg, 95% yield). [α]D20 = -4.1 (c = 1.00, CHCl3) 1H 
NMR (400.1 MHz, CDCl3) δ (ppm) = 7.35 – 7.27 (m, 5H), 4.67 (d, J = 11.89 Hz, 1H), 
4.50 (1H, J =  4.89 Hz, 1H), 4.36 (d, J = 11.89 Hz, 1H), 4.21 – 4.04 (m, 5H), 3.75 – 3.61 
(m, 5H), 2.83 (m, 1H), 2.49 (pentet, J = 7.23 Hz, 1H), 2.1 – 1.55 (m, 10H) 1.15 (s, 9H), 
0.91 (d, J = 6.84 Hz, 3H), 0.86 (t, J = 7.67 Hz, 3H); 13C NMR (100.6 MHz, CDCl3) δ 
(ppm): 172.44, 137.51, 128.24, 127.88, 127.69, 101.71, 82.41, 72.41, 67.72, 66.75, 63.28, 
57.82, 40.71, 38.97, 37.90, 32.09, 28.04, 25.63, 24.62, 24.59, 23.98, 15.16, 11.19; HRMS 
(TOF, ES+) C28H45NO6S [M+H]+ calc’d 524.3001, found 524.2999. 
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(2R,3R)-((1S,7aS)-hexahydro-1H-pyrrolizin-1-yl)methyl2-(benzyloxy)-3 
methylpentanoate (2.49). 
A solution of ester  (50 mg, 0.0914 mmol) in 2 mL of 95:5 trifluoroacetic acid:H2O was 
stirred for 1 hr at room temperature then 0.19 mL of triethyl silane was added. This 
solution was stirred over night and concentrated in vacuo to give a crude, yellow oil. This 
was dissolved in 1 mL DMSO and purified by reverse phase chromatography (2% to 45% 
H2O(0.1%TFA):AcCN) to give (19 mg, 80% yield) as a colorless oil. [α]D20 = (c = 1.12, 
CHCl3) 1H NMR (400.1 MHz, CDCl3) δ (ppm) = 7.33 (m, 5H), 4.66 (d, J = 11.49, 1H), 
4.38 (d, J = 11.50, 1H) 4.15 (dt, J = 11.26, 4.89 Hz, 2H), 3.74 (d, J = 5.65 Hz, 1H), 3.67 
(m, 1H), 3.46 (m, 1H), 3.11 – 2.92 (m, 3H), 2.41 (sextet, J = 6.77 Hz, 1H), 2.01 (m, 1H), 
1.88 – 1.78 (m, 3H), 1.58 (m, 2H), 1.25 (m, 3H), 0.91 (d, J =6.77 Hz, 3H), 0.87 (t, J = 
7.91, 3H); ); 13C NMR (100.6 MHz, CDCl3) δ (ppm): 172.44, 137.48, 128.37, 127.86, 
82.65, 72.53, 64.69, 62.72, 61.18, 44.29, 41.49, 38.00, 31.30, 29.68, 28.75, 28.05, 24.71, 
15.17, 11.28; HRMS (TOF, ES+) C21H31NO3 [M+H]+ calc’d 346.2382, found 346.2381. 
 
OTBSHO
 
(Z)-4-((tert-butyldimethylsilyl)oxy)but-2-en-1-ol  
To a solution of (Z)-but-2-ene-1,4-diol (30 g, 340.5 mmol) in 150 mL of anhydrous DMF 
was added imidazole (34.77 g, 510.7 mmol) and stirred for 30 min. Next tert-
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butyldimethylsilyl chloride (51.32 g, 340.5 mmol) was added in 3 portions. Reaction was 
stirred for 1 hr and then quenched with 300 ml H2O and extracted 3X with ether (100 ml 
ea). Organic was washed with brine (100 ml) and water (100 ml), dried with MgSO4, 
filtered, concentrated in vacuo, and purified by flash column chromatography (3:1 
hexane: EtOAc) to give 85.8 g, 95% yield. 1H NMR (400.1 MHz, CDCl3) δ (ppm) = 5.69 
(m, 2H), 4.25 (dd, J = 4.97 Hz, 2H), 4.19 (d, J = 4.97 Hz, 2H), 0.90 (s, 9H), 0.08 (s, 6H); 
13C NMR (100.6 MHz,CDCl3) δ (ppm) = 134.35, 125.80, 58.90, 26.54, 25.81, 18.16, -
5.30; HRMS (TOF, ES+) C10H22O2Si [M+H]+ calc’d 203.3701, found 203.3702 
 
OTBSBr
 
(Z)-((4-bromobut-2-en-1-yl)oxy)(tert-butyl)dimethylsilane (2.28) 
To a solution of N-bromosuccinimide (28.66 g, 161.027 mmol)  and dimethyl sulfide 
(12.387 g, 199.37 mmol) in 400 ml anhydrous CH2Cl2 at -78°C was added (Z)-4-((tert-
butyldimethylsilyl)oxy)but-2-en-1-ol (15.5 g, 76.679 mmol) at a slow rate. Reaction was 
allowed to warm to rt and stirred for 1.5 hrs. Quench withed a brine solution (400 ml), 
extracted diethyl ether (3X, 150 ml ea), dried with Na2SO4, filtered, concentrated in 
vacuo, and purified via flash column chromatography (6:1 Hexanes: EtOAc) to give 
16.96 g of desired compound. 1H NMR (400.1 MHz, CDCl3) δ (ppm) = 5.74 (m, 2H), 
4.32 (dd, J = 1.34 Hz, 2H), 4.02 (d, J = 8.11 Hz, 2H), 0.90 (s, 9H), 0.08 (s, 6H) HRMS 
(TOF, ES+) C10H22O2Si [M+H]+ calc’d 266.2642, found 266.2699. 
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CHAPTER III 
 
TOTAL SYNTHESIS OF THE INDOLIZIDINE CONTAINING NATURAL 
PRODUCT GRANDISINE D AND AN UNNATURAL ANALOGUE 
 
3.1 Introduction  
 As previously shown, the methodology developed in our lab to generate 
azabicyclic ring systems and azabicyclic lactams can be quiet robust, versatile, and 
useful. This was clearly demonstrated during the rapid synthesis of cremastrine and an 
unnatural analogue in the previous chapters. To further highlight our technology to access 
highly functionalized azabicyclic ring systems, we next focused our attention towards the 
class of natural products known as the grandisines as seen in Figure 3.1. We focused our 
attention on grandisine D due to the fact that at the onset of the project only one synthetic 
effort existed and our route allowed for many possible derivatives to be made around the 
indolizidine scaffold similar to that of grandisine D. 
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Figure 3.1 Grandisine A-G 
 
3.2   Grandisine D Background  
 The grandisine alkaloids were isolated by Carroll and coworkers from the 
Australian rainforest tree Elaeocarpus grandis and all displayed selective human δ-opioid 
receptor affinity. Selective activation of the human δ-opioid receptor is an attractive 
feature due to the possibility to develop new analgesics with more potent and selective 
activity to the human δ-opioid receptor. The first synthetic effort to make grandisine D 
was accomplished by Tamura and co-workers in 2009 in 18 steps (12.5% overall yield) 
employing a Brønsted acid mediated Morita-Bayis-Hillman ring-closure reaction as the 
key step; however, two steps in their synthetic endeavors suffered from poor 
stereocontrol. The summation of their synthetic efforts is summarized in Scheme 3.1, 
where treatment of aldehyde 3.7 with the Brønsted acid, triflic acid, and dimethyl sulfide 
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in acetonitrile generates indolizidone 3.8, where after a number of synthetic 
transformations, the Tamura laboratory was able to generate grandisine D.  
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Scheme 3.1 Tamura and coworkers synthesis of grandisine D 
 
 During the Lindsley laboratories progress towards synthesizing grandisine D, an 
additional synthesis of grandisine D was accomplished by Taylor and coworkers in 2011 
with a key step to generate the azabicyclic motif of an alkyne-acetal cyclization 
procedure to access the indolizidine core. The synthetic efforts by Taylor and coworkers 
generated grandisine D in 13 steps and 10% overall yield starting from the previously 
synthesized structure of N-Boc-prolinol 3.9 (Scheme 3.2). The key synthetic 
transformation of their efforts centered around an alkyne-acetal cyclization of late stage 
intermediate  thioalkyne 3.10 where upon heating in a solution of formic, clean 
cyclization occurred giving them a single enatiomer of thioester 3.11. A number of 
synthetic transformations later and they are able to access grandisine D. Interestingly, 
they were also able to prove that grandisine B is perhaps just an artifact of the isolation 
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procedure by stirring grandisine D in 35% aqueous ammonia to generate grandisine B in 
72% yield. 
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3.2  
Scheme 3.2 Highlights of Taylor and coworkers synthesis of grandisine D and  
grandisine B 
 
 Using the previously described technology developed by the Lindsley laboratory 
of rapidly and efficiently generating diverse azabicyclic ring systems, we achieved a vast 
improvement on the synthesis of grandisine D in both the number of steps and the overall 
yield.  
 
 
3.3   Total Synthesis of Grandisine D 
Our retrosynthetic analysis sought to incorporate methodology developed in the 
Lindsley laboratory that allows for rapid and efficient access to the azabicyclic ring 
structure. Scheme 3.5 outlines our retrosynthesis of grandisine D 3.4. Grandisine D can 
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come about through an aldol between aldehyde 3.13 and chiral ketone 3.12 where the 
α,β-unsaturated aldehyde 3.13 can be generated from the technology developed in the 
Lindsley laboratory of synthesizing azabicyclic ring systems as previously shown. 
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Scheme 3.3 Retrosynthesis of Grandisine D 
 
Starting with commercially available diol 3.15, monosilylation to the TBS ether 
followed by allylic oxidation to the α,β-unsaturated aldehyde 3.16 in 86% yield over two 
steps. The aldehyde in 3.16 is subsequently condensed with tert-butylsulfinamide 3.17, 
with Ti(OEt)4 to remove water from the reaction, which generates the α,β-unsaturated N-
sulfinylaldimine 3.14 in 87% yield. Next, an enantioselective addition of the Grignard 
reagent 3.18 furnishes terminal alkene 3.19 in 79% yield and a greater than 10:1 d.r.. The 
new stereocenter in this molecule is again determined by the existing chirality of the tert-
butylsulfinylamine which directs the addition into the aldimine.  
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Scheme 3.4 Synthetic route to grandisine D 
 
 
The remainder of the route is outlined in Scheme 3.4. 3.19 is alkylated using with 
3-butenyl triflate with LHMDS as the base at -78°C to generate the dialkene product 3.20 
is excellent yield. The diastereomers are separated at this point with normal phase silica 
gel flash column chromatography. Dialkene 3.20 is then subjected to a ring closing 
metathesis reaction using Grubbs 2nd generation catalyst and refluxing in 
dichloromethane to form the unsaturated 6-membered ring 3.21. The primary silyl ether 
is converted to allylic primary alcohol 3.22 using TBAF in THF which proceeds forward 
in 87% yield. Allylic oxidation using MnO2 in dichloromethane garnishes the α,β-
unsaturated aldehyde 3.13 in quantitative yield. Next, a stereoselective dibutylboron 
triflate mediated aldol between aldehyde 3.13 and chiral α,β-unsaturated ketone 3.12 
generates the racemic mixture of the secondary alcohol. The alcohol is oxidized to ketone 
3.33 using a modified Moffatt oxidation with trifluoroacetic anhydride and DMSO with 
triethylamine in dichloromethane at -78°C in 77% yield over two steps. The final step in 
the synthetic scheme involves a global deprotection of the sulfinyl and acetal to the amine 
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and aldehyde, respectively. This intermediate than undergoes an intramolecular reductive 
amination where concentration in vacuo of the imine and addition of polymer supported 
triacetoxyborohydride gives the natural product grandisine D 3.4 in 47% yield.  
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Scheme 3.5 Synthetic Route to Grandisine D (continued) 
 
The entire route, starting from commercially available diol 3.15, was 
accomplished in 11 steps and 16.4% overall yield. Compared to the previous efforts by, 
Tamura and co-workers in 2009 in 18 steps (12.5% overall yield) and Taylor and 
coworkers in 13 steps (10% overall yield), our approach is fewer steps and a significantly 
higher overall yield. Synthesizing grandisine D has again allowed for the clear 
demonstration of the versatility and usefulness of forming azabicyclic ring containing 
natural products and biologically active compounds using our technology. Outlined in 
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Scheme 3.5, is an example of an additional demonstration of the versatility of our 
azabicyclic technology used to generate a completely new unnatural analogue of 
grandisine. Further derivatives around the indolizidine ring of grandisine D are being 
generated and a screening for a new and potentially more potent and selective activator of 
the human δ-opioid receptor will be generated. 
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Scheme 3.6 Synthesis of an Unnatural Analogue of Grandisine D 
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3.7 Experimental Section 
Flame-dried (under vacuum) glassware was used for all reactions. All reagents 
and solvents were commercial grade and purified prior to use when necessary. All 
polymer-supported reagents were purchased from Biotage, Inc. Thin layer 
chromatography (TLC) was performed on glass-backed silica gel. Visualization was 
accomplished with UV light, and/or the use of anisaldehyde and ceric ammonium 
molybdate solutions followed by charring on a hot-plate. Chromatography on silica gel 
was performed using Silica Gel 60 (230-400 mesh) from Sorbent Technologies. IR 
spectra were recorded as thin films and are reported in wavenumbers (cm-1). 1H & 13C 
NMR spectra were recorded on Bruker DRX-400 (400 MHz) or Bruker AV-NMR (600 
MHz) instrument. Chemical shifts are reported in ppm relative to residual solvent peaks 
as an internal standard set to δ 7.26, δ 77.0 (CDCl3) and DMSO-d6 2.50 ppm, 39.51 ppm 
for 1H, 13C respectively). Data are reported as follows: chemical shift, multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, br = broad, m = 
multiplet), coupling constant (Hz), integration. Optical rotations were measured on a 
JASCO P-2000 digital polarimeter. Concentration (c) in g/100 ml and solvent are given 
in parentheses. Low resolution mass spectra (LCMS) were obtained on an Agilent 1200 
LCMS with electrospray ionization. A Micromass Q-Tof API-US mass spectrometer was 
used to acquire high-resolution mass spectrometry (HRMS) data.  The value Δ is the error 
in the measurement (in ppm) given by the equation Δ = [(ME – MT)/ MT] × 106, where ME 
is the experimental mass and MT is the theoretical mass.  The HRMS results were 
obtained with ES as the ion source and leucine enkephalin as the reference.   
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2-(((tert-butyldimethylsilyl)oxy)methyl)prop-2-en-1-ol.   
To a flame-dried flask was added 350mL dry THF, followed by addition of NaH (2.74g, 
113.5 mmol).  To this solution at 0oC was added 2-methylenepropane-1,3-diol (10g, 
113.5 mmol) drop wise.  Mixture was then brought to room temperature and stirred for 
45 min.  Tert-butyldimethylsilyl chloride (17.11g, 113.5 mmol) was added in one batch 
and stirring was continued for an additional 50 min. until complete by TLC.  Reaction 
quenched with H2O, and extracted 3 times with ethyl acetate, washed with brine, dried 
with anhydrous MgSO4, and concentrated in vacuo.  Purification by  flash 
chromatography (4:1 to 1:1 Hex/EtOAc) yielded the product in 20.66 g (89%) as a clear 
oil:  1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.08 (d, J= 7.4 Hz, 2H), 4.25 (s, 2H), 4.17 
(d, J= 6 Hz, 2H), 1.92 (t, J= 6 Hz, 1H), 0.92 (s, 9H), 0.09 (s, 6H); 13C NMR (100.6 MHz, 
CDCl3) δ (ppm): 147.35, 111.08, 65.07, 64.67, 25.78, 18.21, -5.52; HRMS (TOF, ES+) 
C10H23O2Si [M+H]+ calc'd 203.1467, found 203.1466. 
 
O OTBS
 
2-(((tert-butyldimethylsilyl)oxy)methyl)acrylaldehyde (3.16).  
In a flame dried flask, alcohol (13.687g, 67.63 mmol) was dissolved in 200 mL DCM.  
While stirring, MnO2(29.4g, 338 mmol) was added in two batches. Mixture was then 
stirred for 6 hours, until reaction was determined complete by TLC.  Solution was filtered 
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through celite, concentrated in vacuo, and purified by flash chromatography (4:1 
Hex/EtOAc) to yield product in 12.71g (89%) as clear oil. :  1H NMR (400.1 MHz, 
CDCl3) δ (ppm): 9.62 (s, 1H), 6.52 (s, 1H) 6.11 (s, 1H), 4.40 (s, 2H), 0.92 (s, 9H), 0.09 
(s, 6H); 13C NMR (100.6 MHz, CDCl3) δ (ppm): 193.86, 149.74, 133.05, 59.79, 26.06, 
18.52, -5.28; HRMS (TOF, ES+) C10H21O2Si [M+H]+ calc'd 201.1311, found 201.1312. 
 
OTBSN
S
O
 
(R)-N-(2-(((tert-butyldimethylsilyl)oxy)methyl)allylidene)-2-methylpropane-2-
sulfinamide (3.14). 
To a solution of aldehyde (9.00g, 45 mmol) in 400mL DCM was added (R)-2-
methylpropane-2-sulfinamide (6.54g, 54 mmol) and CuSO4 (14.00g, 90 mmol).  Solution 
stirred at room temperature for 16 hours.  Mixture filtered through a pad of celite, with 
DCM as an eluent.  Solution was then concentrated in vacuo and purified by column 
chromatography (4:1 Hex/EtOAc) to yield product in 10.75 g (79%). [α]D20 = 27.276 (c= 
0.01, MeOH);  1H NMR (400.1 MHz, CDCl3) δ (ppm): 8.26 (s, 1H), 6.13 (s, 1H), 5.82 (s, 
1H), 4.48 (dt, J=16, 7 Hz, 2H), 1.20 (s, 9H), 0.93 (s, 9H), 0.09 (s, 6H); 13C NMR (100.6 
MHz, CDCl3) δ (ppm):  163.32, 145.25, 127.42, 61.08, 57.62, 26.09, 22.70, 18.57, -5.23; 
HRMS (TOF, ES+) C14H30O2SiS [M+H]+ calc'd 304.1767, found 304.1765. 
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(S)-N-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-5-(1,3-dioxan-2-yl)pent-1-en-3-
yl)-2-methylpropane-2-sulfinamide (3.19). 
In a flame dried flask under Argon gas was added (2-(1,3-dioxan-2-yl)ethyl)magnesium 
bromide (19.8 mL, 0.5M in THF)to 30 mL THF.  Mixture was then cooled to -78o C, and 
aldimine (1.00g, 3.3 mmol) was added drop wise as a solution in 20 mL THF. Reaction 
was then warmed to -48o C and stirred 16 hours.  Reaction was quenched with NH4Cl and 
brought to room temperature.  Extracted 3 times with ethyl acetate, organic layers 
combined and dried with Na2SO4, concentrated in vacuo, and purified by column 
chromatography (1:1 Hex/EtOAc) to afford product in 1.13 g (80%) as a clear oil: [α]D20 
= 1.596 (c= 0.01, MeOH); 1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.30 (s, 1H), 5.20 (s, 
1H), 5.07 (s, 1H), 4.50 (t, J= 5 Hz, 1H), 4.22 (q, J= 13.5, 18.7 Hz, 2H), 4.07 (dd, J= 5, 7 
Hz, 2H), 3.76 (m, 3H), 3.70 (d, J= 7 Hz, 1H), 2.04 (m, 1H), 1.70 (m, 3H), 1.31 (br d, J= 
13.6 Hz, 1H), 1.20 (s, 9H), 0.91 (s, 9H), 0.08 (s, 6H); 13C NMR (100.6 MHz, CDCl3) δ 
(ppm): 148.66, 112.74, 102.12, 67.08, 64.75, 59.33, 56.00, 31.81, 29.48, 26.14, 26.01, 
22.92, 18.55, -5.20; HRMS (TOF, ES+) C20H42O4SiS [M+H]+ calc'd 420.2604, found 
420.2603. 
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(S)-N-(but-3-en-1-yl)-N-((S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-5-(1,3-dioxan-2-
yl)pent-1-en-3-yl)-2-methylpropane-2-sulfinamide (3.20)  
 To a solution of sulfinamide (100 mg, 0.24 mmol) in 3 mL THF at -78 oC was added 
HMPA (83 µL, 0.48 mmol) and nBuLi (94 µL, 2.5 M, 0.48 mmol). The mixture was 
stirred for 30 mins and a pre-cooled solution of but-3-enyl-trifluoromethanesulfonate (60 
mg, 0.29 mmol) in 1 mL THF was then added slowly to the mixture. The mixture was 
stirred at -78 oC for 30 mins.  The reaction was quenched with water and extracted with 
EtOAc (3x).  The combined organic extracts were washed with brine and dried over 
Na2SO4. Filtration and concentration afforded the crude product, which was purified by 
flash chromatography (1:1 Hex/EtOAc) to afford the product as a pale yellow oil (56 mg, 
87% yield brsm): [α]D
20 = -2.53 (c = 1.00, CHCl3); 1H NMR (400.1 MHz, CDCl3) δ 
(ppm): 5.67-5.77 (m, 1H), 5.32 (brd, J = 1.2  Hz,1H), 5.13 (s, 1H), 5.03 (dd, J = 17.2, 1.6 
Hz, 1H), 5.02 (d, J = 10.0  Hz, 1H),  4.52 (t, J = 4.8  Hz, 1H), 4.05-4.08 (m, 4H), 3.72 (dt, 
J = 12.0, 2.4 Hz, 2H),  3.56 (dd, J = 10.8, 4.4 Hz, 1H), 3.29 (m, 1H), 2.58 (m, 1H), 2.38 
(m, 1H), 2.25 (m, 1H), 1.95-2.23 (m, 3H), 1.67 (m, 1H), 1.50 (m, 1H), 1.32 (dm, J = 13.8 
Hz, 1H), 1.14 (s, 9H), 0.89 (s, 9H), 0.05 (d, J = 8.0 Hz, 6H); 13C NMR (100.6 MHz, 
CDCl3) δ (ppm): 145.6, 135.3, 116.6, 112.9, 102.2, 67.0, 65.0, 61.7, 57.6, 42.2, 34.3, 
32.8, 26.0, 25.9, 24.9, 23.7, 18.4, -5.1, -5.2; HRMS (TOF, ES+) C24H48NO4SiS [M+H]+ 
calc'd 474.3073, found 474.3074. 
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(S)-6-(2-(1,3-dioxan-2-yl)ethyl)-5-(((tert-butyldimethylsilyl)oxy)methyl)-1-((S)-tert-
butylsulfinyl)-1,2,3,6-tetrahydropyridine (3.21) 
To a solution of (1.2 g, 2.54 mmol) in CH2Cl2 (271 mL) was added 2nd Gen. Grubbs 
(107.7 mg, 0.127 mmol). The mixture was refluxed for 1 h and concentrated. The 
resulting crude product was purified by automated flash chromatography (4:1 to 1:1 
Hex/EtOAc) to yield the desired product 1.005 g (89%) as yellow oil: [α]D20 = +2.6 (c = 
1.81, CHCl3);  1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.75 (s, 1H), 4.49 (t, J= 4.8 Hz, 1 
H), 4.09 (m, 4H), 3.73 (dt, J= 12.0, 2.4 Hz, 3H), 3.53 (dd, J= 14.0, 6.4 Hz, 3H), 3.12 (m, 
1H), 2.45 (m, 1H), 2.05 (m, 1H), 1.87-1.79 (m, 1H), 1.78-1.69 (m, 2H), 1.66-1.58 (m, 
2H), 1.32 (br d, J= 13.2 Hz, 1H), 1.20 (s, 9H), 0.90 (s, 9H), 0.06 (s, 6H);  13C NMR 
(100.6 MHz, CDCl3) δ (ppm): 139.0, 122.3, 102.3, 67.0, 65.6, 58.9, 58.8, 37.8, 32.3, 
27.9, 26.1, 26.0, 25.9, 25.2, 23.8, 18.5, -5.1, -5.3; HRMS (TOF, ES+) C22H44NO4SiS 
[M+H]+ calc'd 446.2760, found 446.2762. 
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((S)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((S)-tert-butylsulfinyl)-1,2,5,6-tetrahydropyridin-
3-yl)methanol (3.22) 
To a solution of silyl ether (375 mg, 0.84 mmol) in THF (35 mL) under argon was added 
1.0 M TBAF (1.3 mL, 1.26 mmol) dropwise at 0 oC. The mixture was warmed to rt and 
stirred for 2 h. The reaction was quenched with saturated NH4Cl solution and extracted 
with EtOAc (3x).  The combined organic extracts were washed with water and the dried 
over Na2SO4. Filtration and concentration afforded the crude product, which was purified 
by flash chromatography (9:1 CH2Cl2/MeOH) to afford the product as yellow oil (267 
mg, 96%): [α]D
20 = +5.45 (c = 4.7, CHCl3);   1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.82 
(br s, 1H), 4.52 (t, J= 4.8 Hz, 1H), 4.04 (m, 4H), 3.81 (br d, J= 7.2 Hz, 1H), 3.74 (dt, J= 
2.4, 10 Hz, 2H), 3.57 (q, J= 7.2 Hz, 1H), 3.13 (m, 1H), 2.49 (m, 1H), 2.17 (m, 2H), 1.88 
(m, 2H), 1.77 (m, 2H), 1.62 (m, 1H), 1.33 (d, J= 11 Hz, 1H), 1.21 (s, 9H); 13C NMR 
(100.6 MHz, CDCl3) δ (ppm): 139.81, 124.20, 102.17, 67.05, 65.46, 59.43, 58.97, 37.43, 
32.33, 27.80, 25.88, 25.23, 23.87; HRMS (TOF, ES+) C16H30NO4S [M+H]+ calc'd 
332.1896, found 332.1898 
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(S)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((S)-tert-butylsulfinyl)-1,2,5,6-tetrahydropyridine-
3-carbaldehyde (3.13) 
 To a solution of alcohol (1.69 g, 5.11 mmol) in THF (300 mL) under argon was added 
MnO2 (8.87 g, 102.1 mmol). The mixture was stirred at rt overnight. Filtration over celite 
and concentration afforded the pure product in 99% yield: [α]D20 = +40.0 (c = 0.3, 
CHCl3);   1H NMR (400.1 MHz, CDCl3) δ (ppm): 9.34 (s, 1H), 6.91 (t, J= 4 Hz, 1H), 
4.51 (t, J= 4.4 Hz, 1H), 4.05 (m, 3H), 3.70 (m, 3H), 3.23 (m, 1H), 2.84 (m, 1H), 2.17 (dt, 
J= 5.2, 20 Hz, 1H), 2.04 (m, 1H), 1.7 (m, 4H), 1.32 (br d, J= 12.4 Hz, 1H), 1.20 (s, 9H) ;  
13C NMR (100.6 MHz, CDCl3) δ (ppm): 192.05, 150.64, 143.48, 102.11, 67.02, 59.36, 
57.12, 36.48, 32.67, 28.57, 26.76, 25.88, 23.50; HRMS (TOF, ES+) C16H28NO4S [M+H]+ 
calc'd 330.1739, found 330.1741. 
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(5S,6R)-6-((S)-2-(2-(1,3-dioxan-2-yl)ethyl)-1-((S)-tert-butylsulfinyl)-1,2,5,6-
tetrahydropyridine-3-carbonyl)-5-methylcyclohex-2-enone   
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To a solution of (S)-5-methylcyclohex-2-enone (43.5 mg, 0.395 mmol) in CH2Cl2 (2 mL) 
at -78 oC was added N-ethyl-N-isopropylamine (iPr2NEt) (0.103 mL, 0.592 mmol) and 
nBu2BOTf (0.592 mL, 0.592 mmol). The mixture was stirred at 78 oC for 1 h. Aldehyde 
(86.6 mg, 0.263 mmol) dissolved in CH2Cl2 (2 mL) was added dropwise. The mixture 
was warm to rt and stir for 1.5 h. The reaction mixture was cool -78 oC and quenched 
with 0.1 mL each of MeOH and H2O2, diluted with NaHCO3 and extracted with CH2Cl2 
(3x).  The combined organic extracts were washed with water and the dried over Na2SO4. 
Filtration and concentration afforded the crude product, which was used in the next step 
without purification.  
To a stirred solution of DMSO (38 μL, 0.53 mmol) in CH2Cl2 (7 mL) at -78 ºC was 
added drop-wise trifluoroacetic anhydride (50 μL, 0.35 mmol). After stirring at -78 ºC for 
30 mins, a pre-cooled solution of the crude alcohol dissolved in CH2Cl2 (4 mL). The 
reaction mixture was stirred at -78 ºC for 1 h, then Et3N (0.18 mL, 1.32 mmol) was added 
drop-wise. The solution was further stirred at −78 ºC for a further 20 min, then warmed to 
rt and held for  
1 h. The reaction was quenched by the addition of saturated aqueous NaHCO3 and the 
aqueous layer was extracted with CH2Cl2 (5x), dried over Na2SO4, filtered, concentrated 
in vacuo to give the crude product, which was then purified by  flash chromatography 
(1:20 MeOH/EtOAc) to yield in 5:1 d.r., 88.4 mg (77% over 2-steps) as a pale yellow oil: 
[α]D
20 = +3.4 (c = 1.55, CHCl3);   1H NMR (400.1 MHz, CDCl3) δ (ppm):  6.84 (m, 1H), 
6.02 (d, J= 9.7 Hz, 1H), 5.91 (t, J = 3.8 Hz, 1H), 4.52 (m, 1H), 4.21 (m, 1H), 4.07 (m, 
2H), 3.73 (m, 2H), 3.61 (m, 2H),  3.20 (m, 1H), 2.66 (m, 1H), 2.53 (m, 1H), 2.40 (m, 
1H), 2.34 (m, 1H), 2.10-2.09 (m, 2H), 1.87-1.73 (m, 3H), 1.61 (m, 1H), 1.33 (d, J= 13.4 
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Hz, 1H), 1.20 (s, 9H), 1.08 (d, J= 6.88, 3H);   13C NMR (100.6 MHz, CDCl3) δ (ppm):  
200.98, 200.90, 147.6, 141.5, 128.9, 125.0, 102.2, 72.4, 67.3, 60.2, 59.2, 57.7, 36.34, 
32.29, 30.95, 30.09, 27.97, 25.65, 23.53, 19.72 ; HRMS (TOF, ES+) C23H36NO5S 
[M+H]+ calc'd 438.2371, found 438.2373. 
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Grandisine D (3.4) 
 (43.7 mg, 0.1 mmol) was dissolved in 95:5 TFA : H2O to a final concentration of 0.1 M. 
After stirring for 1.5 h, the mixture was concentrated in vacuo and the residue was 
dissolved in DCE and PS-NaBH(OAc)3 (0.5 g, 0.5 mmol) was added and placed on a 
shaker for 2 h. The beads were filterd off and the solvent was concentrated in vacuo to 
give the crude product. Purification by flash chromatography (28% NH3-MeOH-AcOEt, 
1:10:50) gave grandisine D as pale yellow oil (12.2 mg, 47%). To a solution of the 
grandisine D (9 mg, 0.034 mmol) in DCM (1 mL) at 0 ºC was added dropwise TFA (3.6 
μL, 0.051 mmol). The solution was held at 0 ºC for 30 min, then warmed to rt and held 
for 1 h. The pale yellow solution was concentrated in vacuo to afford TFA salt of 
grandisine D (12.1 mg, Quant.) as pale yellow oil; [α] D
20 +68.8 (c 0.09, MeOH); 1H 
NMR (400.1 MHz, DMSO) δ (ppm): 10.47 (br s, 1H), 7.32 (bdd, J = 4.0, 4.0 Hz, 1H), 
7.16 (ddd, J = 10.0, 6.0, 2.4 Hz, 1H), 5.94 (dd, J = 10.0, 2.4 Hz, 1H), 4.42 (dd, J = 8.8, 
8.8 Hz, 1H), 4.36 (d, J = 12.0 Hz, 1H), 3.58-3.51 (m, 1H), 3.41-3.29 (m, 2H), 3.20-3.06 
(m, 1H), 2.67-2.59 (m, 2H), 2.53-2.33 (m, 3H), 2.27-2.18 (m, 1H), 2.08-1.98 (m, 2H), 
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1.77-1.67 (m, 1H) 0.86 (d, J = 6.0 Hz, 3H); δC (100 MHz, DMSO) 198.4, 196.9, 151.9, 
140.0, 137.3, 128.3, 59.1, 58.0, 52.7, 43.0, 32.7, 32.3, 28.0, 22.4, 20.4, 19.1; HRMS 
(TOF, ES+) C16H22NO2 [M+H]+ calc'd 260.1651, found 260.1650. 
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(S)-N-(3-(1,3-dioxan-2-yl)propylidene)-2-methylpropane-2-sulfinamide (3.34) 
To a solution of 3-(1,3-dioxan-2-yl)propanal (10.1 g, 70.1 mmol) in CH2Cl2 (500 mL) 
was added (S)-2-methylpropane-2-sulfinamide (10.17 g, 84.1 mmol) and CuSO4 (44.6 g, 
280.4 mmol). The reaction mixture was stirred at rt overnight. The mixture was filtered 
through a through celite pad and washed with CH2Cl2. Concentration in vacuo gave the 
crude product which was purified by automated flash chromatography (4:1 to 1:1 
Hex/EtOAc) to yield the desired product 15.6 g (90%) as yellow oil: [α]D20 = +209.3 (c = 
0.86, CHCl3); 1H NMR (400.1 MHz, CDCl3) δ (ppm): 8.11 (t, J = 4.0 Hz, 1H), 4.62 (t, J 
= 4.8 Hz, 1H), 4.10 (dd, J = 6.0, 4.8 Hz, 2H), 3.76 (m, 2H), 2.64 (sextet, J = 4.0 Hz, 2H), 
2.07 (m, 1H), 1.93 (m, 2H), 1.32 (dm, J = 13.8 Hz, 1H), 1.18 (s, 9H);  13C NMR (100.6 
MHz, CDCl3) δ (ppm): 169.1, 101.0, 67.0, 56.7, 30.8, 30.7, 25.8, 22.5; HRMS (TOF, 
ES+) C11H22NO3S [M+H]+ calc'd 248.1320, found 248.1319. 
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(S)-N-((S)-1-(1,3-dioxan-2-yl)hex-5-en-3-yl)-2-methylpropane-2-sulfinamide (3.35) 
In-Mediated allylation were done according to procedures published by Lin and co-
workers. To a reaction flask containing sulfinimine (14.5 g, 58.7 mmol) and indium 
powder (27.0 g, 234.8 mmol) was added saturated aqueous NaBr solution (1174 mL, 
(1062.4 g of NaBr)) followed by the allyl bromide (36.8 mL, 234.8 mmol). The resulting 
suspension stirred at rt for 24 h. The reaction was quenched by the addition of saturated 
aqueous NaHCO3 and filtered through a pad of celite. The aqueous layer was extracted 
with EtOAc (3x), dried over Na2SO4, filtered, concentrated in vacuo to give the crude 
product as >19:1 dr, which was then purified by  flash chromatography (1:1 Hex/EtOAc) 
to yield the allylation product in 14.7 g (87%) as a pale yellow oil: [α]D20 = +38.9 (c = 
1.43, CHCl3); 1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.77 (m, 1H), 5.16 (d, J = 4 Hz, 
1H), 5.13 (s, 1H), 4.51 (t, J = 4.5 Hz, 1H), 4.08 (dd, J = 5, 6.3 Hz, 2H), 3.74 (dt, J = 10, 
2.2 Hz, 2H), 3.30 (m, 1H), 3.23 (d, J = 6.5 Hz, 1H), 2.37 (m, 2H), 2.05 (m, 1H), 1.63 (m, 
3H), 1.33 (br, J = 14 Hz, 1H), 1.19 (s, 9H);  13C NMR (100.6 MHz, CDCl3) δ (ppm): 
133.9, 119.0, 101.9, 66.8, 55.8, 55.0, 40.5, 31.3, 29.2, 25.7, 22.6;  HRMS (TOF, ES+) 
C14H28NO3S [M+H]+ calc'd 290.1790, found 290.1790. 
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(S)-N-((S)-1-(1,3-dioxan-2-yl)hex-5-en-3-yl)-N-(2-(((tert-
butyldimethylsilyl)oxy)methyl)allyl)-2-methylpropane-2-sulfinamide (3.37) 
To a solution of sulfinamide (1.4 g, 4.84 mmol) in 25 mL DMF at -20 oC was added 
LiHMDS (9.7 mL, 1 M in THF,) and the mixture was stirred for 20 mins at -20 oC and 20 
mins at rt. The mixture was cooled back to -20 oC and (3.83 g, 14.83 mmol) was then 
added slowly to the mixture and the reaction was slowly. The mixture was stirred at -20 
oC for 30 mins and rt overnight.  The reaction was quenched with saturated NH4Cl 
solution and extracted with EtOAc (3x).  The combined organic extracts were washed 
with water and the dried over Na2SO4. Filtration and concentration afforded the crude 
product, which was purified by flash chromatography (4:1 to 1:1 Hex/EtOAc) to afford 
the product as a pale yellow oil (2.06 g, 90%): [α]D
20 = -2.3 (c = 0.85, CHCl3); 1H NMR 
(400.1 MHz, CDCl3) δ (ppm): 5.74-5.84 (m, 1H), 5.23 (s, 1H), 5.14 (s, 1H), 5.03 (m, 
1H), 4.48 (t, J = 5.2  Hz, 1H), 4.05 (m, 4H), 3.94 (brd, J = 17.2 Hz, 1H), 3.72 (dt, J = 
12.0, 2.4 Hz, 2H), 3.14 (d, J = 17.2 Hz, 1H), 2.96 (q, J = 7.2 Hz, 1H), 2.40 (dq, J = 28.2, 
6.8 Hz, 2H), 1.89-2.09 (m, 2H), 1.61-1.80 (m, 3H), 1.32 (dm, J = 13.8 Hz, 1H), 1.29 (s, 
9H), 1.19 (s, 9H), 0.06 (s, 6H); 13C NMR (100.6 MHz, CDCl3) δ (ppm): 145.2, 136.3, 
117.2, 111.7, 102.2, 67.0, 66.9, 64.8, 62.6, 58.0, 53.6, 45.5, 39.5, 33.3, 27.3, 26.0, 25.9, 
23.8, 18.5, -5.2, -5.3; HRMS (TOF, ES+) C24H48NO4SiS [M+H]+ calc'd 474.3073, found 
474.3076. 
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(S)-2-(2-(1,3-dioxan-2-yl)ethyl)-5-(((tert-butyldimethylsilyl)oxy)methyl)-1-((S)-tert-
butylsulfinyl)-1,2,3,6-tetrahydropyridine (3.38). 
To a solution of (1.0 g, 2.11 mmol) in CH2Cl2 (260 mL) was added 2nd Gen. Grubbs (89.5 
mg, 0.106 mmol). The mixture was refluxed for 1 h and concentrated. The resulting crude 
product was purified by automated flash chromatography (4:1 to 1:1 Hex/EtOAc) to yield 
the desired product 0.845 g (90%) as yellow oil: [α]D20 = -1.7 (c = 0.0181, CHCl3);  1H 
NMR (400.1 MHz, CDCl3) δ (ppm): 5.62 (d, J= 4.8 Hz, 1H), 4.51 (t, J= 4.8 Hz, 1 H), 
4.09 (dd, J= 4, 7.6 Hz, 2H), 4.03 (d, J= 4 Hz, 1H), 3.73 (m, 3H), 3.34 (m, 2H), 2.52 (m, 
1H), 2.06 (m, 1H), 1.89 (dd, J= 6, 12.4 Hz, 1H), 1.80 (m, 1H), 1.68 (m, 2H), 1.57 (m, 
2H), 1.33 (br, d, J= 12.4 Hz, 1H), 1.16 (s, 9H), 0.89 (s, 9H), 0.05 (s, 6H);  13C NMR 
(100.6 MHz, CDCl3) δ (ppm): 135.3, 118.3, 102.3, 67.0, 65.5, 58.7, 56.8, 37.2, 32.9, 
28.0, 27.0, 26.1, 25.9, 23.5, 18.5, -5.2; HRMS (TOF, ES+) C22H44NO4SiS [M+H]+ calc'd 
446.2760, found 446.2764. 
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((S)-6-(2-(1,3-dioxan-2-yl)ethyl)-1-((S)-tert-butylsulfinyl)-1,2,5,6-tetrahydropyridin-
3-yl)methanol. 
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 To a solution of (300 mg, 0.67 mmol) in THF (27 mL) under argon was added 1.0 M 
TBAF (1.01 mL, 1.01 mmol) dropwise at 0 oC. The mixture was warmed to rt and stirred 
for 2 h. The reaction was quenched with saturated NH4Cl solution and extracted with 
EtOAc (3x).  The combined organic extracts were washed with water and the dried over 
Na2SO4. Filtration and concentration afforded the crude product, which was purified by 
flash chromatography (9:1 CH2Cl2/MeOH) to afford the product as yellow oil (210 mg, 
95%): [α]D
20 = -116.1 (c = 4.7, CHCl3);   1H NMR (400.1 MHz, CDCl3) δ (ppm): 5.64 (br 
d, J= 4.8 Hz,  1H), 4.49 (t, J= 4.8 Hz, 1H), 4.05 (dd, J= 11.6, 4.0 Hz,  2H), 3.91 (m, 3H), 
3.71 (tt, J= 12.0, 3.6, Hz, 2H), 3.33 (m, 2H), 2.96 (br s, 1H), 2.52 (br d, J= 17.6 Hz, 1H), 
2.04 (m, 1H), 1.87 (br dd, J= 17.6, 5.2, Hz, 1H), 1.79-1.68 (m, 2H), 1.59-1.49 (m, 2H), 
1.31 (d, J= 12.4 Hz, 1H), 1.14 (s, 9H); 13C NMR (100.6 MHz, CDCl3) δ (ppm): 135.7, 
119.8, 101.9, 66.8, 65.2, 58.6, 56.9, 36.6, 32.6, 27.7, 26.8, 25.7, 23.3; HRMS (TOF, ES+) 
C16H30NO4S [M+H]+ calc'd 332.1896, found 332.1897. 
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(S)-6-(2-(1,3-dioxan-2-yl)ethyl)-1-((S)-tert-butylsulfinyl)-1,2,5,6-tetrahydropyridine-
3-carbaldehyde (3.39) 
 To a solution of alcohol (150 mg, 0.45 mmol) in THF (30 mL) under argon was added 
MnO2 (796 mg, 9.16 mmol). The mixture was stirred at rt overnight. Filtration over celite 
and concentration afforded the pure product in Quant. yield: [α]D20 = -8.1 (c = 1, MeOH);   
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1H NMR (400.1 MHz, CDCl3) δ (ppm): 9.34 (s, 1H), 6.91 (d, J= 5.2 Hz, 1H), 4.51 (t, J= 
4.4 Hz, 1H), 4.12 (m, 3H), 3.72 (tt, J= 12.0, 2.8 Hz, 2H), 3.49 (m, 2H), 2.79 (dm, J= 3.2 
Hz, 1H), 2.22 (ddd, J= 19.2, 6.0, 2.0 Hz, 1H), 2.06 (m, 1H), 1.75-1.51 (m, 4H), 1.32 (br 
d, J= 12.4 Hz, 1H), 1.18 (s, 9H) ;  13C NMR (100.6 MHz, CDCl3) δ (ppm): 191.9, 146.5, 
138.7, 101.5, 66.7, 58.7, 56.6, 33.6, 32.3, 29.3, 26.8, 25.6, 23.2; HRMS (TOF, ES+) 
C16H28NO4S [M+H]+ calc'd 330.1739, found 330.1739. 
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(5S,6R)-6-((S)-6-(2-(1,3-dioxan-2-yl)ethyl)-1-((S)-tert-butylsulfinyl)-1,2,5,6-
tetrahydropyridine-3-carbonyl)-5-methylcyclohex-2-enone (3.40) 
To a solution of (S)-5-methylcyclohex-2-enone (43.5 mg, 0.395 mmol) in CH2Cl2 (2 mL) 
at -78 oC was added N-ethyl-N-isopropylpropylamine (iPr2NEt) (0.103 mL, 0.592 mmol) 
and nBu2BOTf (0.592 mL, 0.592 mmol). The mixture was stirred at 78 oC for 1 h. 
Aldehyde (86.6 mg, 0.263 mmol) dissolved in CH2Cl2 (2 mL) was added dropwise. The 
mixture was warm to rt and stir for 1.5 h. The reaction mixture was cool -78 oC and 
quenched with 0.1 mL each of MeOH and H2O2, diluted with NaHCO3 and extracted 
with CH2Cl2 (3x).  The combined organic extracts were washed with water and the dried 
over Na2SO4. Filtration and concentration afforded the crude product, which was used in 
the next step without purification.  
To a stirred solution of DMSO (38 μL, 0.53 mmol) in CH2Cl2 (7 mL) at -78 ºC was 
added drop-wise trifluoroacetic anhydride (50 μL, 0.35 mmol). After stirring at -78 ºC for 
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30 mins, a pre-cooled solution of the crude alcohol dissolved in CH2Cl2 (4 mL). The 
reaction mixture was stirred at -78 ºC for 1 h, then Et3N (0.18 mL, 1.32 mmol) was added 
dropwise. The solution was further stirred at −78 ºC for a further 20 min, then warmed to 
rt and held for 1 h. The reaction was quenched by the addition of saturated aqueous 
NaHCO3 and the aqueous layer was extracted with CH2Cl2 (5x), dried over Na2SO4, 
filtered, concentrated in vacuo to give the crude product, which was then purified by  
flash chromatography (1:20 MeOH/EtOAc) to yield the desired product 57, 77.0 mg 
(67% over 2-steps) as a pale yellow oil: [α]D20 = +3.6 (c = 0.27, CHCl3);   1H NMR 
(400.1 MHz, CDCl3) δ (ppm): 6.96 (m, 1H), 6.86 (br d, J= 5.2 Hz, 1H), 6.02 (d, J= 10 
Hz, 1H), 4.51 (m, 1H), 4.08 (m, 3H), 3.82 (m, 1H), 3.72 (m, 3H), 3.53 (br d, J=  18.8 Hz, 
1H), 3.39 (m, 1H), 2.77 (m, 1H), 2.67 (m, 1H), 2.56 (m, 1H), 2.09 (m, 3H), 1.75 (m, 1H), 
1.59 (m, 2H), 1.32 (br d, J= 12.4 Hz, 1H), 1.16 (s, 9H), 0.99 (d, J= 6.4 Hz, 3H);  13C 
NMR (100.6 MHz, CDCl3) δ (ppm): 197.73, 196.79, 149.98, 138.64, 129.34, 101.97, 
67.00, 59.85, 58.91, 56.27, 34.79, 33.08, 32.90, 32.62, 29.04, 27.28, 25.88, 23.39, 22.86, 
20.20; HRMS (TOF, ES+) C23H36NO5S [M+H]+ calc'd 438.2371, found 438.2371. 
 
N
O
O
H
H
TFA
 
(5S,6R)-6-((S)-1,2,3,5,8,8a-hexahydroindolizine-6-carbonyl)-5-methylcyclohex-2-
enone  (3.41). 
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(40.7 mg, 0.093 mmol) was dissolved in 95: 5 (TFA: H2O) to a final concentration of 0.1 
M. After stirring for 1.5 h, the mixture was concentrated in vacuo and the residue was 
dissolved in DCE and PS-NaBH(OAc)3 (0.5 g, 0.465 mmol) was added and placed on a 
shaker for 2 h. The beads were filterd off and the solvent was concentrated in vacuo to 
give the crude product. Purification by flash chromatography (28% NH3-MeOH-AcOEt, 
1:10:50) gave as pale yellow oil (11.8 mg, 49%). To a solution of (10 mg, 0.0386 mmol) 
in DCM (1 mL) at 0 ºC was added dropwise TFA (4.1 μL, 0.058 mmol). The solution 
was held at 0 ºC for 30 min, then warmed to rt and held for 1 h. The pale yellow solution 
was concentrated in vacuo to afford TFA salt of (13.7 mg, Quant.) as pale yellow oil; [α] 
D
20 +2.1 (c 0.05, MeOH);  
1H NMR (600.1 MHz, DMSO) δ (ppm): 10.27 (br s, 1H), 7.33 (m, 1H), 7.15 (ddd, J = 
10.2, 6.6, 2.4 Hz, 1H), 5.96 (dd, J = 10.2, 2.4 Hz, 1H), 4.35 (d, J = 12.0 Hz, 1H), 4.30 (d, 
J = 16.2 Hz, 1H), 3.80 (m, 1H), 3.74-3.68 (m, 1H), 3.30 (br s, 1H), 3.12-3.09 (m, 1H), 
2.89 (dt, J = 19.8, 4.2, Hz, 1H), 2.55-2.44 (m, 3H), 2.32-2.27 (m, 1H), 2.32-2.27 (m, 1H), 
2.24-2.19 (m, 1H), 2.06-1.99 (m, 1H), 1.97-1.91 (m, 1H), 1.64 (q, J = 10.2 Hz, 1H) 0.87 
(d, J = 6.0 Hz, 3H); δC (150.9 MHz, DMSO) 198.0, 196.8, 151.9, 140.9, 134.6, 128.4, 
60.4, 59.5, 52.2, 47.8, 32.7, 32.6, 28.7, 27.6, 19.9, 19.2; HRMS (TOF, ES+) C16H22NO2 
[M+H]+ calc'd 260.1651, found 260.1651. 
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